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Experiences of Being Maintained on a Ventricular Assist Device 
Thesis Abstract 
This thesis explores the experiences of patients receiving cardiac support from two different 
types of ventricular assist device (VAD).  The literature review focuses on the decision-
making experience of patients and caregivers considering implantation of a left ventricular 
assist device (LVAD).  The LVAD is a type of long-term/durable VAD which enables 
patients to be discharged from hospital.  The literature review employed a thematic synthesis 
of the qualitative literature arriving at three major themes Context, Mechanism and Outcome.  
The synthesis proposes that decision-making is affected by Context and Mechanisms for both 
patients and caregivers which in turn leads to the theme Outcome.  Context and Mechanism 
can be better understood by healthcare professionals by the third theme of Outcome.   
The research paper explores the experiences of patients who have undergone short-
term ventricular assist device (ST-VAD) support as an emergency procedure.  The short-term 
ventricular assist device provides temporary cardiac support while a patient is in hospital.  
Participants in the research paper completed interviews which were then analysed using an 
Interpretative Phenomenological Analysis framework.  Four superordinate themes are 
presented following the participants journey; (1) Crisis and the fragile nature of life, (2) “You 
adapt, you’ve got no choice”, (3) Moving on, (4) The change in me.   
The final section of the thesis comprises the author’s critical appraisal and reflections 
during the research process.  The critical appraisal provides an opportunity for further 
reflection on the existential aspect of the VAD, the author’s professional development in the 
area of clinical health psychology, involving participants in the research process and clinical 




This thesis reports research undertaken between April 2016 and October 2017 for the 
Lancaster University Doctorate in Clinical Psychology.  The work presented within this 
thesis is my own except for those instances where due reference has been given to other 
authors.  This thesis has not been submitted for the award of a higher degree elsewhere.   
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EXPERIENCE OF L-VAD DECISION-MAKING 
Abstract 
Background:  The use of left ventricular assist device (LVAD) in end stage heart failure is 
increasingly common.  The decision-making process can be complex for patients and 
caregivers and there has been a rise in qualitative studies exploring their experiences of this.        
Objectives: The aim of this study was to synthesise the qualitative literature regarding 
patients and caregivers’ experiences of decision-making related to LVAD.  
Methods: A search of CINAHL, PubMed, Academic Search Complete, PsychINFO and Web 
of Science was conducted on the topic of LVAD and decision-making. The articles were 
synthesised using a formal process of thematic synthesis. 
Results:  Three domains surrounding LVAD decision-making were identified: Context, 
Mechanism and Outcome.  Context and Mechanism related to specific thoughts and emotions 
which fed in to the decision.  Outcome related to the thoughts and feelings following the 
decision.  
Conclusions:  Decision-making surrounding LVAD can be emotive and stressful and there 
may be factors involved that are not fully supported and understood by healthcare 
professionals.  As well as the factors which make up Context and Mechanism, it is important 
for healthcare professionals to understand the “Outcome” described by patients and 
caregivers.  It can be understood that Outcome can feedback into the understanding of 
Context and Mechanism and as such aid in tailoring support.   Professionals can then support 
patients and caregivers in the most suitable ways.  In this way, “Outcome” feeds back into the 
understanding of “Context” and “Mechanism”.   
Key Words: Left ventricular assist device, LVAD, Decision-making, Heart failure 
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According to the National Heart Failure Audit (2015-2016)1, approximately 900,000 people 
in the United Kingdom have heart failure.  Heart failure encompasses problems with heart 
function, due to the heart being unable to fill or empty effectively.  In the UK the commonest 
reason for heart failure is the inability of the left ventricle to contract strongly enough to push 
the blood around the body.  This leads to an increase in pressure in the left atrium which 
prevents the blood leaving the lungs.  Symptoms of heart failure include breathlessness, 
fatigue and swollen ankles.1  Patients with New York Heart Association (NYHA) class IV are 
considered as having end stage heart failure (exhibit symptoms of heart failure at rest) and are 
eligible for transplant or LVAD.2  End stage heart failure is also typified by “discomfort with 
any physical activity”(p. 4) and the need for complete rest.2 
Heart failure can be managed by pharmacological treatment and invasive procedures, such as 
heart transplant.3 Heart transplant is the treatment of choice for end stage heart failure but 
there is a scarcity of donor organs.  Amongst patients under the age of 60 between 10 and 15 
patients per million need a heart transplant.  There are sufficient donors for two per million 
which means that there are around 150 transplants a year in the UK.4,5  Left ventricular assist 
devices (LVAD) were devised as a bridge to transplant or recovery for those awaiting a donor 
heart.2 LVADs are implanted pumps that assist the heart in pumping blood throughout the 
body.  These devices have a cable that connects the pump to a controller and power source 
which is worn outside of the body6 see Figure 1.  Left ventricular assist devices (LVADs) 
have become more common (as a bridge to transplant or recovery) due to the waiting periods 
for donor hearts or when transplantation is not appropriate (as a destination therapy (DT)).6, 7 
In the UK currently LVAD is not licensed as a destination therapy however in other countries 
such the USA it is.  Between 1 April 2004 and 31 March 2014 438 patients were bridged to 
transplant with LVAD.8   
Figure 1 here: The left ventricular assist device (LVAD) 
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These devices enable patients to be discharged from hospital.  LVAD support is 
intended to extend life expectancy and improve quality of life for patients with chronic end-
stage heart failure.10 However, the patient can experience complications, including 
respiratory failure, ventricular arrhythmia, right heart failure, arterial arrhythmia, renal 
failure, device malfunction, stroke (haemorrhagic or thrombotic), gastrointestinal bleeding 
and driveline infection. 11 These are serious problems that can impact negatively on quality of 
life and prognosis for patients supported with LVAD.  Ben-Gal and Jaarsma12 state that the 
new generations of LVAD have a high success rate, however along with the potential medical 
complications there are lifestyle challenges involved.  The patient needs to carry a battery 
pack, they must not get the battery pack and controller wet and they must avoid damage to 
the driveline exit site which restricts their movement in bed.  The complications and changes 
to lifestyle need to be fully understood by patients and make the decision-making process of 
considering LVAD implantation very difficult especially when the alternative is, at best, 
restricted quality of life .  This decision is illustrated in Figure 2.      
Insert Figure 2. 
A number of studies have been conducted into the impact of living with an LVAD on 
different aspects of life, such as the psychosocial impact,13,14 life style adjustments15,16 and 
quality of life.17,18  More recently, a meta-synthesis was conducted into the adaptation and 
coping of patients with an LVAD.19 It reported four distinct stages: Pre-LVAD, implant 
hospitalisation, early home adaptation and late home adaptation.  During the Pre-LVAD stage 
patients spoke of wanting to relieve the heavy symptom burden due to heart failure 
(particularly shortness of breath and mobility over a prolonged time) and this reinforced the 
decision to have LVAD implanted.  It was also reported that the undesirable nature of being 
dependent on another person and this dependence having an impact on the patient’s role and 
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personal identity.  The patients’ pursuit of independence was often thwarted by complications 
following implantation.19     
The perspective of caregivers has also received attention.  A recent qualitative meta-
synthesis20 regarding caregivers’ perceptions about caring for an adult LVAD patient 
reported three stages: “early stage”, “middle stage” and “late stage”.  Within each domain 
there were different themes.  Caregiving in the “early stage” involved an “emotional 
rollercoaster” when understanding how sick the patient was followed by their key role in 
decision-making regarding LVAD placement (theme: “decision: no option”).  Once the 
LVAD was in place caregivers described where they learnt the necessary skills to look after 
the patient but were anxious about being able to manage emergencies at home (theme “leave 
it [the LVAD] at the hospital”).  The “middle stage” covered the period at home for 
caregivers and patients.  Caregivers described “fragility of the patient and the associated 
anxiety, fear and hypervigilance” followed by “recognition of a need to adapt”.  After 
caregivers adapted to their new caregiving role they recognised their “transformed life”.  The 
“Late stage” referred to the end of the LVAD; this varied between those who went on to have 
transplant or those who had LVAD fitted as destination therapy.     
Rationale for the present review 
Previous qualitative studies and reviews have focused on the impact of LVAD on the 
experiences of patients and caregivers, their quality of life, adaptation and coping.12-20 
However, there has been a recent rise in qualitative studies that have examined the experience 
and process of decision-making surrounding LVAD, for both patients and caregivers.  
Despite the growing importance of this process there has been no detailed synthesis of the 
data concerning the patient and caregiver experience of decision-making. This thematic 
synthesis21 was therefore conducted to gain an overview of the decision-making experiences 
of patients and caregivers concerning LVAD.  Therefore, the question this thematic synthesis 
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addressed is: “How do patients and caregivers experience and view decision-making related 
to LVAD?”  This review will increase our understanding, which will help multidisciplinary 
healthcare professionals to support patients and their families’ pre-decision-making, during, 
and post-decision-making surrounding LVAD.   
Method 
Data Search 
Potential studies for this thematic synthesis were obtained through searching the following 
databases: CINAHL, PubMed, Academic Search Complete, PsychINFO and Web of Science.  
Appropriate search terms were used, augmented by using the thesaurus or MeSH terms, and 
the appropriate Boolean operators, as shown in Table 1.  A librarian was consulted to help 
refine the search terms and strategies to ensure all relevant studies were found.  The searches 
were conducted between the 26th and 31st December 2016.  
Table 1: Search terms table 
Inclusion and exclusion criteria 
Articles were included in the thematic synthesis if they: (1) were written in English; (2) were 
published in peer-reviewed journals, as these are subject to quality assessment; (3) employed 
whole or in part qualitative methods with written quotes from patients or caregivers; (4) 
included the experiences of patients or caregivers in decision-making regarding or during 
LVAD.  The articles were required to explore patient or caregiver experience of decision-
making concerning LVAD as a theme or component of the results reported.  Articles were 
excluded if their focus was on children because of the complexity of decision-making for 
parents of young children which would likely be different experiences for a spouse, parent or 
caregiver of an adult.   If the article focused solely on end of life decision-making it was 
excluded from the analysis.  Articles were also excluded if they: (1) did not elicit data from 
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patients or caregivers themselves; or (2) where the quotes might be attributed to healthcare 
professionals. 
Results of search 
The results of the search strategy are outlined in the PRISMA22 diagram (Figure 2).  Initially 
678 articles were reviewed using their titles, abstracts, once duplicates were removed.  Those 
that appeared to meet the criteria were subject to detailed analysis via reading full text to 
determine whether they met the inclusion criteria. Studies were not included if they were: not 
specifically about VAD, focused on children, were centre reports, reviews or medical 
commentaries, quantitative or systematic reviews with economic evaluation.  Hand searching 
the references in the relevant articles yielded two articles that were suitable for inclusion, and 
two articles were excluded during full text reviewing.  When multiple reports of the same 
study were found, the articles were compared and only selected if each article presented 
distinct findings based on different study aims and questions about the same material.  
Following the implementation of the inclusion and exclusion criteria nine articles were 
relevant.  Hand searching of references yielded two further studies.  This resulted in 11 
papers reporting the experience of decision-making surrounding LVAD of patients (n=167, 
22 were the same sample in two studies) and caregivers (n=97).  
Figure 2: PRISMA flowchart 
Table 2 provides details of the 11 articles 23-33 (aims, method, summary of findings). 
The experience of patients was reported in eight articles and caregivers in six articles.  Nine 
of the articles originated from the USA where the use of LVAD is well established.  All of 
the articles originated from jurisdictions where LVAD is licensed both as bridge to transplant 
and destination therapy.  As they are qualitative studies it is not surprising that the largest 
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number of participants in any study was 45.  The articles considered were not homogenous, 
differing in their purpose and study design. 
Table 2: Article Characteristics 
Quality Assessment 
The Critical Appraisal Skills Programme (CASP)34 was used to consider the quality of the 
studies used in the thematic synthesis.  The CASP has two screening questions regarding 
clarity of the aims and appropriateness of the methodology, followed by eight quality 
questions that range from in depth methodological appropriateness to ethical relevance.  Each 
of the studies passed the screening questions.  Each paper was evaluated using the CASP 
items in conjunction with the rating system proposed by Downe35 (Table 3).   
Table 3: Researcher’s CASP score 
An experienced colleague and the researcher independently appraised each of the 11 
selected papers and rated them according to the perceived reliability of their conclusions 
which were discussed as there was initially some discord in ratings.  The researcher’s views 
can be seen in Table 3 and the consensus is shown in Table 4.  
Table 4: CASP Consensus 
The CASP scores were not used to exclude papers but to compare, examine and 
critique the research to add context to the results.36 The ratings given are related to the quality 
of reporting and not necessarily the quality of the study itself.  The quality of the studies was 
good to excellent, with eight papers showing no or few flaws at consensus.   
Thematic synthesis 
The aim of this literature review was to analyse and synthesise published qualitative research 
to explore decision-making experiences of patients and caregivers.  Thematic synthesis aims 
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to achieve analytical abstraction at a higher level by rigorously examining common and 
overlapping elements.21 This approach takes into account the concerns of both meta-
ethnography and grounded theory.37  Free codes of findings are organized into ‘descriptive’ 
themes, which are then further interpreted to yield ‘analytical’ themes.38  Thematic synthesis 
was employed to focus on patient and caregiver experiences of decision-making in the 
context of LVAD.  This methodology was chosen for two reasons.  Firstly, it enabled the 
analysis of substantive literature in decision-making across the duration of LVAD.  Secondly, 
it enabled the description of influencing factors on decision-making for this population and 
the development of analytical themes that could be applied across the decision timeline.   
From an epistemological perspective, thematic synthesis may be classified as critical 
realist, where our knowledge of reality is mediated by our perceptions and beliefs.39  The 
technique involves the development of descriptive and analytical themes that aim to “go 
beyond the primary studies to generate new interpretive constructs, explanations, or 
hypotheses”21 (p.1). The chosen thematic synthesis approach involved examining all the text 
labelled as ‘results’ or ‘findings’ in study reports.  The three stage system of thematic 
synthesis was employed;21 organising line by line codes into descriptive themes and 
developing analytical themes from them.  The individual sources were input into and 
analysed in NVivo.40  Figure 3 details the descriptive to analytical themes and Table 5 for 
theme translational table.   
Stage 1: Each line of text is coded according to meaning and content.  This technique allows 
the comparison and translation of concepts from one study to another. The use of line by line 
coding enabled the comparison and translation of concepts from one study to another.41  
Stage 2: Similarities and differences between codes were noted, where appropriate codes 
were grouped and given meaningful labels. This process resulted in 17 descriptive themes.    
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Stage 3: Stage three involved generating analytical themes, going beyond the findings of the 
primary studies to generate additional concepts, understandings or hypotheses.  This iterative 
process involved sorting and aggregating the descriptive themes until a clear pattern emerged 
with minimal overlap between the new themes.21   
Figure 3: Descriptive to analytical themes 
Table 5: Theme translational table 
Synthesis 
Three major themes, with sub-themes, were identified as being central to decision-making:  
1. Context (illness and quality of life, medical professionals, emotions)  
2. Mechanism (information and understanding, values)  
3. Outcome (adjusting expectations, decision regret, optimism)  
The relationship between the themes are illustrated in Figure 4.  The themes of Context and 
Mechanism feed into the decision-making process.  The Outcome theme concerns the way 
participants deal with consequences of their decision.  For healthcare professionals 
understanding the Outcome of decision-making is important in helping the patient to make an 
informed decision.    
Figure 4: Thematic Map 
The themes which were extracted from the analysis of the data were “Context”, 
“Mechanism” and “Outcome”, while not precluding alternative interpretations, this fits most 
closely with a critical realist approach.39 The strength of a critical realist approach is that it 
recognises that patients apply the evidence to their individual and personal circumstances.  
The information provided and understanding of that information  is the “Mechanism,” 
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individual and personal circumstance is the “Context” and the “Outcome” reflects the effects 
of the decision. 
Theme 1: Context 
The theme “Context” encompassed the patients’ current level of illness and quality of life as 
a way to understand decisions regarding the LVAD.  Ten of the 11 papers reviewed described 
quality of life and illness impacting on decision-making.23-32  Low quality of life and high 
symptom burden would suggest that the LVAD would be a necessary intervention; for 
example: “…it [heart failure] was killing him.  He had no strength. He had no quality of life. 
He was just existing”31  (p174).  Those who declined LVAD believed that although their 
quality of life was decreasing, LVAD would not improve this sufficiently enough to justify 
going through the implantation of the LVAD.29 Blumenthal-Barby and colleagues reported: 
“In rare cases where patients heard about the LVAD option earlier and medical management 
was still an option, they preferred to postpone the decision until they absolutely had to.23 
(p1185).  Indeed, one decliner stated: “I feel good…I haven’t felt like I need something right 
now” 24 (p838).  Decliners also reported that further complications due to LVAD would deter 
them from the device: 
“And I know I’m going to have problems.  So you know, like what’s the point? And why 
would I want to deal with that you know? It’s just…life is complicated enough as it is, you 
know? I don’t need any more complications”29 (p68). 
The second important aspect of context was the advice provided by medical professionals 
described in nine of the 11 papers.23,25,27-33  A good relationship between the medical team, 
patient and caregivers was necessary.  Patient and caregiver decision-making was “rooted in 
conversation with their health care team”33 (p370) and decisions were often guided by the 
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good faith, trust and confidence that patients and caregivers had in the medical team.  Indeed, 
Blumenthal-Barby and colleagues quoted the following participant in their study:  
“They said that the LVAD is probably the best way to go. And I trust these doctors with his 
life. And when they said that, that’s what we decided. I didn’t really ask for statistics. I just 
went with what they said. They said it would work, so I trusted them”23 (p1185).   
The way in which the LVAD was explained was also an important factor for patients and 
caregivers: “I was able to think over the need of implanting an LVAD, because doctors did 
not communicate this option in an aggressive way; they described its potential as a bridge to 
transplant”32 (p224). 
The third aspect of context was the emotional nature of making decisions and the stress and 
anxiety described by patients and caregivers.  Caregivers felt less fear and anxiety when the 
final decision was made by the patient.  It was described that “emotion was pervasive”29 (p68) 
and “patients became emotional and even shed tears during their interviews when recalling 
the decision-making time period” 30 (p378) but less was understood about the mechanism of 
emotion during the decision-making process and as such this could be seen as context.  
Emotion was present for those who accepted and declined the LVAD.  One decliner stated; “I 
just said, when it’s my time I’m ready. (starting to choke up…cry). I mean I know what’s on 
the other side. So it doesn’t really bother me” 30(p377).  Furthermore at times emotions were 
unspoken: 
“At the time of decision-making, most caregivers reported feeling [destination therapy] 
LVAD would offer the patient more time and improved quality of life.  Less often articulated 
was the fear that the patient would not survive surgery or would experience persistent 
complications” 31 (p174). 
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Theme 2: “Mechanism” 
The theme “Mechanism” encompassed the thoughts, feelings and attitudes of patients and 
their caregivers making decisions, whether the decision was to accept or decline an LVAD.  
Ten of the eleven reviewed papers discussed aspects of the mechanisms of decision-
making.23,24,26-33  Decision makers tended to fall into two categories, those who were 
reflexive and would make a decision without deliberation and those who were reflective who 
would weigh up the risks and benefits of the decision.  Thus, according to McIlvennan and 
colleagues:  
“nearly all patients clearly fell into one of two decision-making approaches: (1) an automatic 
process of decision-making where fear of death and a singular focus on [destination therapy] 
LVAD as a chance to prolong life over-rode any weighing of additional risks and benefits and 
(2) a reflective process where participants reasoned through risks and benefits of [destination 
therapy] LVAD”30 (p77). 
 
Information and understanding 
Seven articles reviewed 23,24,26,28-30,33 described the nature of information sharing and 
understanding of this.  For patients, they described the impact of medication and illness on 
receiving and understanding medication.26,28,30  During decision-making patients and 
caregivers described that there was a lot of information to take in and people often felt 
overloaded by the amount and technical nature of the information.  One caregiver said:  
“Well, I mean, I hear what he said.  They did explain it and they had a video that explained 
what the VAD was and everything.  The gist of it was that he was too sick to understand it. 
And I was too tired to totally get the gist of it. I mean you understood. I don’t think he did”26 
(p811). 
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There were benefits for caregivers being present when information was discussed, as 
Blumenthal-Barby and colleagues reported: 
“The doctor would say stuff and I would hear what I thought the doctor said. But me hearing 
it and then trying to tell her [my wife] —I’m telling her what I thought I heard. So, by the 
time it gets back around to the doctor, he’s confused and we’re all confused”23 (p1186).   
Caregivers were often the people who helped patients to receive and translate the information 
that was given regarding decisions. “I have been through so many things with my husband, 
and I write everything down, and I research. You see this book [referring to book of notes]? 
It’s too important. That’s my husband’s life” 23 (p1186).  Patients and caregivers described 
that hearing from others both before and after LVAD implantation was important in the 
decision-making process.  Indeed, “talking to other patients who are living with [LVAD for 
destination therapy] was cited as the most valuable information one could receive” 33 (p372). 
Overall caregivers were grateful for the information shared.  Patients and caregivers, 
when asked, described a range of informational needs regarding LVAD placement including 
change to lifestyle, complications, prognosis and financial.23  Lifestyle included aspects such 
as changes to mobility, impact on hobbies, the prospect of being a burden or losing 
independence and medication regimes.  Information needs regarding complications included 
infections, bleeding and what to do in an emergency.  Aspects of prognosis that patients and 
caregivers wanted information about included life expectancy without the VAD, length of 
LVAD treatment and probability of transplant.  In terms of financial information, patients and 
caregivers felt they need to know about out of pocket costs, changes to work life and changes 
to insurance cost.   
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Values 
Values played a strong role in decision-making as described in nine of the 11 articles.23,24,27-33  
Values related to being able to engage with the world and increase quality of life, to live 
longer for family, to be with family, and bodily integrity including not wanting to be “opened 
up” or choosing an LVAD as it enabled them to “keep the same heart”.23,24  For caregivers 
there was a struggle between wanting the patient to live and respecting the patient’s decision:   
“Factors included apprehension about being widowed, a need for help with responsibilities, 
such as raising grandchildren, or the perceived inability of a family with other recent trauma 
to cope with further loss. In contrast, a few caregivers focused heavily on their belief that this 
was an extremely personal decision, and the patient should not be influenced by others’ 
opinions” 31(p175). 
One of the most frequently discussed aspects of decision-making was that “there was 
no alternative” and “you either want to live or you don’t”23 (p1185).  For some patients and 
caregivers, LVAD signified the only option for patients to continue to live.  For those who 
declined the LVAD they believed that “death was an acceptable alternative to continuing a 
life of pain or suffering”30 (p377).  McIlvennan and colleagues stated that those who used a 
reflective decision process “viewed death as an option worthy of consideration, examined the 
meaning of their lives, and reflected on their values, particularly around quality versus 
quantity of life preferences”30 (p377).  Magid and colleagues described that both accepters 
and decliners of LVAD wanted to relieve distress.  However, acceptors felt that the LVAD 
would enable this, “I wanted to be alive or dead. I don't like to be sick”29 (p67), whereas 
decliners felt that the LVAD would not “…you are coughing and choking and one day you 
are up and the next day you're down. It's just… I've had enough of it”29 (p67).  
Further value related influences included: spirituality, finances, and the media - the 
Cheyney effect;29,30  McIlvennan and colleagues reported that one patient had said “…it 
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wasn’t really a deciding factor…but I found out that Vice-President Cheyney had an LVAD in 
him and he had it for 12 years before he had a heart transplant…that is a pretty good 
indication there that it would work” 30(p378) the information stated by patients in terms of 
the media was not always accurate.  Further values reported by decliners included LVAD 
effecting mobility, it being an experimental intervention, and concerns that it would affect 
their chance of receiving a heart transplant. 24 
Theme 3: Outcome 
The theme “Outcome” encompassed the thoughts, feelings and attitudes of patients and 
caregivers following the decision.  Ten of the eleven articles reviewed reported experiences 
about the outcome following decision-making. 23, 25-33  Caregivers who had the final decision 
due to patient illness reported a sense a burden and uneasiness in terms of responsibility for 
making the right decision;25,27,31 “Wondering if I was doing the right thing …either way it 
turned out, I was the one that was going to take the brunt of everything, which was scary”25 
(p145).  For patients, there was low reported decision regret if the decision made was 
consistent with their values.23 Decision regret was connected to continued illness following 
LVAD decision.  There was a sense that the decision to proceed with LVAD was “just the 
beginning” and that life was not automatically easier once LVAD was in place.  Indeed, the 
“Outcome” theme related to patients and caregivers needing to adjust expectations following 
decision-making.  When searching for information, patients and caregivers reported that 
many of the stories online and in the media reported people “returning to normality”.  For 
example, Dick Cheyney was reported to be living well following LVAD implantation and 
subsequent heart transplant in 2012 which lead to the “Cheyney Effect” and a sense of 
security for accepting the device.30 
Adjusting expectations included reframing what “good health” meant now the LVAD 
was implanted.  Patients and caregivers expected to be feeling better following LVAD 
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implantation, “no…um I expected to be better. I am not as better as I expected.  It is not 
coming as fast as I want, but I’m told by the professionals that I am on target” 29(p68).  
Kitko and colleagues found that participants described “an improved quality of life and 
decreased symptom burden in the post implantation”28 (p97) but did not feel that the LVAD 
had met their expectations.  Optimism, a positive attitude and dedicated caregiver aided 
patients post-LVAD implant; Ottenberg and colleagues reported “daily frustrations were 
tempered by an optimistic spirit and a willingness to be patient with the recovery process”33 
(p371).  Adapting to the changes brought by the LVAD required resilience. 
There was a sense that patients hoped that the LVAD would lead to being symptom free 
however there were setbacks and barriers in recovery and “good health” such as infections 
and continuing symptoms.33 These barriers were disheartening for patients and caregivers. 
Patients could sometimes remember being told there were risks to the LVAD but this had not 
been taken on board at the time, “I have had as many admissions with my heart failure. I 
remember them telling me risks but not sure I was listening”28 (p97).  Although disheartened 
by their experience, there was a sense that, for those who had accepted the device, they were 
“happy to be alive”28 (p97).  Caregivers reflected on their experience of living with an LVAD 
recipient.  Although there was some disappointment at the outcome even those who were 
involved in the decision-making process appeared pragmatic:  
“not that I would change my decision but I had to make it without him. He was so sick, he was 
out of it. The times he is not doing well [with the LVAD], I feel guilty, I wonder if he would have 
made the same decision”27 (p198). 
For those who felt “well” and had not had a number of complications there was a sense 
that feeling well might not last.  Articles also reported patients starting to outlive the 
expectancy of the device.  For those where LVAD was destination therapy, uncertainty was 
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related to no further treatment options.  For those hoping for transplant there was uncertainty 
as to whether they would be eligible:  
“I received the LVAD as a bridge to transplant…I am medically stable and that is good, but now I 
am not moving on the transplant list … the LVAD is really a double-edge sword because I feel 
like it is me keeping from getting a heart”28 (p97). 
For those who declined LVAD, adjusting expectations included revisiting the initial 
decision to decline the LVAD:  “These candidates explained that, although they made their 
initial decision reﬂexively, they were willing to revisit their decision once medical 
management no longer provided relief”24 (p837). 
Discussion 
The current synthesis describes three themes involved with decision-making surrounding 
LVAD.  The themes “Context” and “Mechanism” feed into the decision-making process and 
the theme “Outcome” refers to the thoughts and feelings following decision.  It is important 
for healthcare professionals to understand the “Outcome” described by patients and 
caregivers as this can aid the professionals in supporting patients and caregivers in the most 
suitable ways.  In this way, “Outcome” feeds back into the understanding of “Context” and 
“Mechanism”.   
McIlvennan, and colleagues42 interviewed mechanical circulatory support (MCS) 
coordinators regarding the preimplantation decision process.  These healthcare professionals 
spoke of the complicated decision that patients make and believed that for optimal decision-
making to occur three central components were required:  
“1) decision support with early introduction of [destination therapy] LVAD therapy 
and alternative options, 2) an iterative process and multidisciplinary team and 3) a 
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careful approach balancing tension between conveying enough detail about the 
process yet not overwhelming patients”42 (p222).   
Sagin and colleagues43 describe the involvement of palliative care specialists in the 
decision-making phases of LVAD and the increased acknowledgement for the need of 
advanced care planning from the beginning.   In line with this synthesis and studies with 
healthcare professionals, the timing of information regarding LVAD needs to happen sooner 
in the heart failure journey.  Participants often reported being too sick or overwhelmed to 
fully comprehend information they were given about the LVAD.  By not fully understanding 
the consequences of information this could lead to decision regret and the need to adjust 
expectations of life with an LVAD.  If information was provided sooner it would enable a 
more collaborative, balanced decision.  During this process, it would be important to include 
clear discussions regarding end of life care.  Although in the UK, LVAD is used as a bridge 
to transplant, not all patients will recover sufficiently or reach candidacy for transplant.   
Edlund and colleagues44 conducted a questionnaire study to investigate patient’s 
understandings of the LVAD.  They reported that patients struggled to understand the 
procedure and device that they are consenting to which may be heightened for those with 
lower levels of verbal ability.  Information needs to be provided in a range of formats with a 
balanced view regarding risks and benefits.  As discussed in the synthesis, the role of peers 
would be highly beneficial to the process and enable patients and caregivers to have a clear 
understanding of the life adjustments that might take place.   
Within the perspective piece by Boothroyd and colleagues45 they propose a model of 
key elements of informed decision-making.  Within this they suggest that informed decision-
making should include the following: 1) the timing of discussions should occur prior to 
implantation and be revisited as situations change, 2) discussions should include multi-
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disciplinary healthcare professionals, family/caregivers and peer mentors as well as the 
patient, 3) information should include risks and benefits in both physical and quality of life 
aspects for patients and caregivers, 4) information should be clear, up to date and patient 
preferences respected.   
The meta-synthesis regarding adaptation and coping for patients with LVAD19 
highlighted the use of emotion-focused and problem-focused coping.  Emotion-focused 
coping included intentionally having a positive attitude, sense of humour and passing on 
knowledge and support to others going through LVAD implantation.  Problem-focused 
coping related to building skills and routines to live as independently as possible.  Both of 
these styles of coping can be challenged by unexpected complications such as infections or 
over-protection from caregivers and the impact on the patients’ sense of control and 
autonomy.  These different coping strategies are part of the context and mechanism of the 
decision-making process as discussed above.  Healthcare professionals need to understand the 
context and mechanism as it applies to the individual patient and in understanding the 
differences in adjusting expectations which could be supported by person-centred healthcare 
from the outset.   
Strengths and limitations of the review 
This study incorporated the experiences of decision-making surrounding LVAD support, the 
choice particularly whether or not to have the device implanted, and used rigorous methods 
for systematic review that included a comprehensive search of published studies using 
predetermined criteria.  Study reporting was assessed according to the CASP framework 
which allowed readers to judge for themselves the quality of included studies and 
generalisability to their own context.  This study combined eligible studies of experiences in 
treatment decision-making from patients’ and caregivers’ perspectives in an attempt to 
achieve the higher level analytical abstraction that is aimed for in thematic synthesis.21   
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Reviewer one was from a clinical psychology background and reviewer two was an 
experienced reviewer from a general medical background.  Although there was discord 
between the initial scores given by the reviewers both reviewers provided similar positive 
ratings for all the papers.  There was a tendency for reviewer one to be more positive overall.  
These minor differences were resolved through discussion and consensus scores agreed for 
all papers. This may have been due to different application of the scoring system.  The need 
for discussion ensured that the incision of some papers that might otherwise be excluded.  
Ben Gal and Jaarsma12 reported that there may be differences in how patients and 
families from a range of cultures might perceive the LVAD and the withdrawal process.  This 
could reflect the value related to bodily integrity.  As such, it would be beneficial for future 
research that looks specifically at the views of culturally and linguistically diverse people 
regarding decision-making about LVAD support.  The way that the data has been aggregated 
by papers in this synthesis means that it is not possible to establish and comment on the 
cultural homogeneity of the sample. 
As the majority of papers in the review originated from the USA broad claims about 
the generalisability of the results to the worldwide LVAD population should be avoided.  The 
licensing of LVAD across countries is different.  The majority of the LVAD decision-making 
studies highlight the licensing protocols within territories that allow LVAD as destination 
therapy.  This does not mean that decision-making and LVAD information should not be 
shared in early stages.  As in those countries that do not currently employ LVAD as 
destination therapy, there is still the chance that patients will live with LVAD in situ until the 
end of their life.     
  
1-22 
EXPERIENCE OF L-VAD DECISION-MAKING 
Conclusions 
This thematic synthesis of qualitative studies on decision-making surrounding LVAD support 
shows that there are a number of factors involved in decision-making which may not be fully 
supported by healthcare professionals at this time.  Factors influencing decisions included the 
emotive and stressful timing of decision which can inhibit the understanding of information 
which may lead later to decisional regret.  This synthesis highlights the need for optimal 
timing for information and education regarding the LVAD and the need for peer mentors to 
be included in the education process.    
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What’s New? 
• LVAD decision-making was understood by the Context (including illness and quality 
of life) and Mechanism (including patient’s understanding of information). 
• People are less likely to regret their decision if it is made in line with their values.  












Figure 1. The left ventricular assist device (LVAD).  
Ventricular Assist Device. Unmodified from Madhero88 
(https://en.wikipedia.org/wiki/Ventricular_assist_device#/media/File:Ventricular_assist_devi
ce.png) , reproduced under the conditions Creative Commons Licence 
(https://creativecommons.org/licenses/by-sa/3.0/).  
A more detailed but copyrighted picture is available from Rizzieri AG, Verheijde JL, Rady 
MY, McGregor JL. Ethical challenges with the left ventricular assist device as a destination 
therapy. Philos Ethics Humanit Med. 2008; 3(20): 1-15. https://doi.org/10.1186/1747-5341-
3-20  
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Figure 2. Decision tree illustrating patient options and potential outcomes. 
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Studies included in 
qualitative synthesis 
(n =11) 
Figure 3: PRISMA flow chart. 
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from LVAD offered to 
interview; 10 candidates 
declined for an average of 
224 days before agreeing 
to LVAD placement 
 
Perceiving the LVAD as affecting 
transplantation 
Perceptions about illness severity 
Importance of bodily integrity 
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now what? 




To explore the 
influence of 
cognitive bias 









interview data from 
previous study 




22 patients, 15 accepted, 
7 declined 






• Optimism bias/affective 
forecasting 
• Halo effect 
 
Decliners: 
• Affective forecasting 
• Reflective reasoning 
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22 patients, 15 accepted, 
7 declined 
Dominant decision processes: “there 
was no choice” versus “I thought 
about it an awful lot” 
 
Secondary influences: 


























17 caregivers, 16 
caregivers of accepters of 
LVAD, 1 caregiver of 
LVAD decliner 
Decision Context 
• Tension: hope and reality 
• Years of Poor Health 
• Sense of Urgency 
• Ineligibility for Transplant 
Decision Process 
• Tension: Wanting loved one to 
live and wanting to respect their 
wishes 
• Influences of relationships with 
the clinicians 
• Making the decision 
Decision Outcome 
• Tension: gratitude and a feeling 
of burden 
• Reflecting on the decision 
 
Modica et al, 
2015, 32 Italy 
Investigate 







28 patients with an 
LVAD, 22 implantation 
Concepts influencing LVAD 
acceptance:  
The characteristics of the device 
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as BTT, 6 implantation as 
destination therapy. 
The experience the disease 
The peculiar nature of the heart as 
diseased organ 
Doctor-patient communication 
The opportunity to share the 
experience 
Psychological characteristics of the 
patient  
Ottenberg et 







their care from 












12 patients, median time 
from DT implantation to 
interview was 1.37 years, 
caregivers welcomed but 
not formally enrolled in 
the study 
Theme 1: Preparedness planning 
Theme 2: new lease on life 
Theme 3: optimizing support 
networks 
Theme 4: systemic limitations 
Theme 5: reflections on time 
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Barby et al, 
2015 
B A A A A A A A 
Bruce et al, 
2015 B A B B A B B A 
Kaan et al 
2010 A A B B C B A A 
Kirkpatrick 
et al, 2015 A A A A B A A A 
Kitko et al, 
2013 A A A A B A A A 
Kitko et al, 
2016 A A A B A A A A 
Magid et al, 
2016 A A A A A A A A 
McIlvennan 
et al, 2014 A A A A A A A A 
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McIlvennan 
et al, 2015 A A A A A A A A 
Modica et al 
2014 B B B C B B B B 
Ottenberg et 
al, 2014 A A A A A A A A 
         
 Quality rating: A- No or few flaws, high credibility, transferability, dependability and confirmability, B- 
some flaws unlikely to affect the quality, C- some flaws which may affect quality and D- significant 
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Table 4: Consensus CASP Quality Scores 
 Reviewer 1 Reviewer 2 Consensus 
Blumenthal-Barby 2015 A B B 
Bruce 2015 B- A A 
Kaan, 2010 B A A 
Kirkpatrick 2015 A B-C B 
Kitko 2013 A A-B A 
Kitko 2016 A A-B A 
Magid 2016 AA B A 
McIlvennan 2014 AA B A 
McIlvennan 2015 AA A-B A 
Modica 2014 B B B 
Ottenberg 2014 AA A-B A 
Quality rating: A- No or few flaws, high credibility, transferability, 
dependability and confirmability, B- some flaws unlikely to affect the 
quality, C- some flaws which may affect quality and D- significant flaws 
which are likely to affect credibility, transferability, dependability and 








• Context- patient illness 
and quality of life 
• Medical Team 
• Realisation 
• Support Network 










• Quality of life 
• Uncertainty 





Figure 4. Descriptive themes and how they relate to final analytical themes.  Descriptive 
themes marked by bullet points 
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Table 5: Theme Translational Table of Main Themes and Sub-themes and the related papers 
 Theme one: Context Theme two: Mechanism Theme three: Outcome 













Barby 2015 X X  X X X X 
Bruce 2015 X   X X   
Kaan, 2010 X X X    X 
Kirkpatrick 
2015 X  X X  X X 
Kitko 2013 X X   X X X 
Kitko 2016 X X X X X X  
Magid 2016 X X X X  X  
McIlvennan 
2014 X X X  X   
McIlvennan 
2015 X X X  X X X 
Modica 
2014 X X X  X X  
Ottenberg 


















• Illness and Quality 
of life, 







• Decision Regret 
“Mechanism” 





Figure 5. Thematic Diagram Providing Themes with Accompanying Sub-themes. 
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Each manuscript must include the following upon submission:  
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verifications/copyright transfer questions upon submitting. The corresponding author 
completes this when submitting during the "additional information step." This is where 
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any acknowledgments, credits, or disclaimers, including funding sources and conflicts of 
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• Please do not use abbreviations in the title or any headers on your manuscript.  
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the article. If it is a research article (including psychometric studies) or brief report, 
prepare a structured abstract with the following headings: (1) background; (2) objective; 
(3) methods; (4) results; and (5) conclusions. If the article is not a research article, please 
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• Keywords: Include 3 to 5 key words that describe the contents of the article. To identify 
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people find your article, identify it as relevant, and increase your citations.  
• Each research article or review of the literature must include a table entitled, “What’s 
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with implications for practice. Place this section on a separate page after the references. 
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bullets only) a summary of the important clinical points of the article.  
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• Written permission, including complete source, for any borrowed text, tables, or figures 
submitted by mail or fax (form attached to the end of this file).  
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Abstract 
Background:  The short-term ventricular assist device (ST-VAD) can be used to stabilise 
patients following a cardiac event or deteriorating heart failure to enable recovery or 
understanding of the most effective next intervention.  There are very few studies exploring 
the experience of having a ST-VAD implanted as an emergency procedure.   
Objectives: The aim of this study was to explore the lived experiences of people following 
implant of a ST-VAD as an emergency procedure.   
Methods: This qualitative study included eight participants (5 men and 3 women) who were 
interviewed and transcripts analysed using Interpretative Phenomenological Analysis.   
Results: Participants described four superordinate themes regarding their journey with ST-
VAD support: (1) Crisis and the fragile nature of life, (2) “You adapt, you’ve got no choice”, 
(3) Moving on, and (4) The change in me.   
Conclusions: The ST-VAD had a considerable effect on participants, but following the 
initial shock and crisis participants learned to adapt to the restrictions of the ST-VAD.  
Participants described moving on from the hospital to which they had become attached. 
Participants also reflected on positive changes and their changed priorities following the 
emergency procedure.  This suggests strong links with existing posttraumatic growth 
literature. 
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A ventricular assist device (VAD) is a mechanical pump that is used to support heart function 
and blood flow for people who have heart failure.  The device takes blood from a lower 
chamber of the heart (ventricle) and helps pump it to the body and vital organs, just as a 
healthy heart would.1   Left ventricular assist devices (LVAD) support the left ventricle and 
hence pump blood around the body. Right ventricular assist devices (RVAD) support the 
right ventricle and pump blood to the lungs for oxygenation. The device assists the heart and 
differs from total artificial hearts. 
In addition to the distinction between left and right VAD, there are further distinctions 
relating to short-term or longer-term use.  Long-term VADs (LT-VAD) enable patients to be 
discharged from hospital as part of the device is implanted within the body (with a cable that 
connects the pump to a controller and power source which is worn outside the body).2  The 
short-term VAD (ST-VAD) is an external cardiac device for people supported in intensive 
care. Short-term devices offer temporary circulatory support to stabilise patients with acute 
cardiogenic shock and to rest the heart;3 this provides time to determine the most effective 
intervention.  ST-VADs therefore offer a bridge to decision regarding the most useful 
intervention, which can include later removal, exchange to implantable LVAD, or heart 
transplant.4 Between 1 April 2004 and 31 March 2014 179 patients received ST-VAD in the 
UK .  134 subsequent to critical cardiogenic shock and 42 were in progressive cardiovascular 
decline and the reasons for three patients were not reported.5 There is no universal definition 
of “short-term VAD”; however, in line with Takayama and colleagues,6 the current research 
will define ST-VAD as “mechanical circulatory support devices used only in the in-patient 
treatment setting” (p2).  This study focuses on the experiences of people who have undergone 
ST-VAD support as an emergency procedure. 
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Although there is little research on ST-VAD, several studies have been conducted on 
LT-VAD and patients’ experiences and perspectives of the device.  These studies have 
reported that patients who temporarily or permanently rely on LT-VADs for end stage heart 
failure may face complex psychological, emotional and relational problems.7  A literature 
review regarding quality of life for individuals with VAD7  reported improvements in quality 
of life from 1-3 months post-implant as measured by health-related quality of life scales.  
However, they point out that emotional distress is often unexplored within these trials and 
further qualitative research could aid a better understanding of emotional health and the use 
of support.8 
Qualitative research has explored the impact of LT-VADs on patients and their lives, 
including quality of life during and after VAD support, perceptions and concerns of patients 
and caregivers, and psychosocial and sexual concerns.9 These studies report themes of  
adjustment,9 mechanical dependence,11,12 and perceived control.13, 14 In a meta-synthesis, 
Abshire and colleagues15 reported four distinct stages of adaptation of LVAD patients: 1) pre-
LVAD, 2) implant and hospitalisation, 3) early home adaptation and 4) late home adaptation.  
Each stage included physical, psychological and social domain tasks to aid coping. 
One of the studies included in the meta-synthesis conducted an interpretative 
phenomenological analysis (IPA) pilot study9 with LT-VAD patients (N=4) and ST-VAD 
patients (N=2); those with LT-VAD all went on to have a transplant whereas those with ST-
VAD went on to recovery.  Two themes were reported: “Body and Self” and “Trust”.  Within 
the “body and self” theme there were sub-themes of shock, restrictions, scarring and 
infection.  There were similarities in the journeys of each of their patients in that they 
experienced a physical decline and had to come to terms with an intrusive mechanical device 
keeping them alive but being constantly aware of vibration and noise. 
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The theme of “Trust” had two elements, the initial element of trusting the device and 
then the post-VAD period trusting either their own or donated heart. There had also been a 
lack of time to prepare family members who were shocked by the device when they first saw 
it.  Due to the small sample size, it cannot be said whether the emergency nature of ST-VAD 
had a greater impact on patients’ experiences than planned LT-VAD.  Those who received 
the VAD device as an emergency procedure had no recollection of this period and needed to 
process their lack of control both cognitively and emotionally.  This suggests that the 
emergency aspect of treatment may need to be better understood.  During the implantation 
and hospitalisation phase participants reflected on their high dependency on others; this phase 
may be particularly pertinent for those in the current study.   
ST-VAD shares similarities with Extracorporeal Membrane Oxygenation (ECMO).  
ECMO is a rescue intervention for patients who are at significant risk of dying from acute 
lung or heart failure where blood is actively pumped through an artificial lung that is external 
to the body and provides gas exchange and blood pressure support for hours to weeks until 
the underlying condition has resolved.  The similarities with ST-VAD is that they are both 
short-term interventions that aim to bridge patients to the next intervention or recovery.  Both 
interventions can be used in emergency situations and require the support of an intensive care 
unit. Tramm and colleagues16 conducted a thematic analysis of experiences of ECMO 
survivors. Themes reported from this study included: (1) dealing with crisis, (2) being in 
ICU, (3) good and bad experiences, (4) ICU memory, (5) significant others and (6) existence 
today and tomorrow.  Two themes are of relevance to the current study: “dealing with crisis” 
and “existence today and tomorrow”.  Within the “dealing with crisis” theme the authors 
described that most participants had experienced a crisis due to rapid symptom deterioration 
and emergency use of ECMO treatment.  Within the “existence today and tomorrow” theme, 
all participants recognised and articulated their acute care as a matter of life and death.  
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Consequently, all participants expressed happiness about survival and thanked staff and 
helpers.  Participants reported gaining new life perspectives and priorities such as living in 
the here and now or focusing on the future possibilities.   
In summary, current research tends to focus on the impact for people with LT-VAD 
which may be a different experience from those who have a ST-VAD. ST-VADs have 
external pumps, the patient’s mobility is severely limited and patients have intensive nursing 
support within a critical care environment.  The ST-VAD offers critically “ill” patients a 
bridge to decision.  Research has been conducted into the quality of life and experiences of 
people who have a LT-VAD often as a bridge to transplant, bridge to recovery or destination 
therapy, but little research has focused on the experience and psychological impact of ST-
VAD implant.   
Aim 
The current study aims to examine the lived experiences of people following ST-VAD 
implant as an emergency procedure in transition to either heart transplant or LVAD. This will 
help to inform whether there might be a need for improved psychological care.    
Methodology 
Study Design 
This study used an interpretative phenomenological analysis (IPA) approach to the collection, 
analysis and interpretation of the data.17  One of the aims of IPA is to “explore in detail 
individual personal and lived experiences and to examine how participants are making sense 
of their personal and social worlds”18 (p36); this encourages the researcher to focus on 
contexts and perspectives of individuals as well as a group. IPA provides a systematic and 
reflective way of the researcher working through five stages of learning.19  Transcribing the 
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data corresponds to stage 1 (noticing), initial coding corresponds to stage 2 (making sense) 
and the forming of the superordinate themes corresponds to stage 3 (meaning making).  The 
analytic process continues with stage 4 (working with meaning) as the individual participant 
responses are compared and contrasted and the final stage of the analysis is stage 5 
(transformative learning).  The role of the researcher in IPA is to make sense and make 
meaning rather than simply collecting and collating data.20    The study did not aim to 
generate a theoretical-level account as in grounded theory.17   Furthermore, grounded theory 
was not designed to discover theory related to people living outside their normal lives (p 
106).21  This study aimed to “add depth and purpose” which may not be offered by thematic 
analysis (p22).20  At the point of data collection, the interview schedule and research 
approach had been informed by an IPA framework.   
In accordance with the principles of IPA, the interview schedule was kept fairly open to allow 
participants to discuss their own personal experiences in relation to their journey through the 
emergency procedure to further intervention.   
Participants 
One of the main facets of IPA is that the sample recruited to be interviewed should be 
homogenous and closely defined to ensure similarity of experience being investigated and to 
allow for a detailed interpretative account of each of the participants interviewed.  To conduct 
an in depth phenomenological analysis it is necessary to focus on a small sample to allow a 
rich analysis and interpretation to be performed (Figure 1).22  Eight participants were 
recruited from one cardiothoracic transplant unit in the UK.  Table 1 provides details of each 
participant including pseudonym, age, reason for ST-VAD, time on ST-VAD, time since ST-
VAD and further intervention.  Diagnosis was that reported by participants, it was not 
verified with the medical team to maintain confidentiality.  Inclusion criteria were: 
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1) People who have undergone ST-VAD as an emergency procedure 
2) People discharged from ICU and therefore outpatients   
3) People who have capacity to give consent.  
Potential participants were excluded from the study if they did not speak English or had 
special communication needs.  A timeframe since discharge from hospital was not specified 
within the inclusion/exclusion criteria.  At the time of the interviews, participants had been 
off ST-VAD for between one and 36 months.  The bias of retrospective reporting is 
recognised but considered to be outweighed by the opportunity to interview patients who had 
managed the various challenges of post ST-VAD support.   
Insert Figure 1 
Insert Table 1  
Recruitment 
Recruitment took place in one of six specialised NHS sites providing multidisciplinary 
services to heart and lung transplant patients in the UK.  Posters detailing the nature of the 
study were displayed in the hospital waiting room and participants were recruited by 
members of the cardiothoracic team.  Potential participants were either given participant 
information packs while attending outpatient appointments, or they were posted if they were 
not due in for an appointment within a three-month timeframe.  Potential participants were 
also telephoned by known clinicians to be informed of the study.  This was the most reliable 
source of recruitment as all participants were recruited this way.    
Participants were asked to complete an expression of interest form if they were 
interested in taking part in the study.  Alternatively, participants could contact the chief 
investigator directly or consent for a member of the transplant team to pass on their contact 
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number.  Following this, the chief investigator contacted those participants who had 
expressed an interest to determine whether they still wanted to engage in the study and to 
answer any questions they had.   Interviews were arranged at times convenient to each 
participant and took place in the participants’ homes or at the hospital site.  
Data Collection  
Semi-structured interviews were used to gain an insight into patient experiences.  This 
method was chosen to establish rapport with participants and to allow the researcher 
flexibility in exploring areas of interest.  In this way it was hoped that interviews would 
follow participants’ interests or concerns rather than pre-determined topics of interest 
highlighted by the interviewer.17 The semi-structured interview schedule included topics 
relating to the chronology of the illness trajectory, transition to and time on ST-VAD, further 
intervention and hopes for the future (Section Four, Appendix A).  
Confidentiality, the right to withdraw data and the debriefing process were explained 
before each interview began and patients were then asked to sign a consent form (Section 
Four, Appendix D).  All interviews were audio recorded and the first interview completed 
was analysed by the chief investigator and discussed with the academic supervisor to 
determine whether the questions used were appropriate to the research question as well as to 
the nature of the interview (i.e. open and non-leading).  Interviews lasted between 35 minutes 
and 2 hours 50 minutes; the average across eight interviews was around one and a half hours.  
Participant’s chose or were assigned a pseudonym following the interview. 
Data analysis 
The interviews were transcribed by the chief investigator and were read through several times 
to gain a full understanding of the data.  They were input into and analysed in NVivo.23  For 
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each of the transcripts, notes were initially made.  These notes were both descriptive and 
interpretative and were designed to capture key words, ideas, or emerging interpretations.  
Once this initial note making stage had been completed, higher level, interpretative comments 
were made and these formed the basis of the emerging themes.  A set of main themes was 
produced for each transcript and then the sets of themes from each participant were translated 
into a set of superordinate themes for the whole dataset.17 Themes were discussed with the 
research and field supervisors and a reflective diary was kept to document thought processes 
and focus on the participant’s interpretations.  This process is illustrated in Appendix 2-B for 
Theme 2 to maintain the transparent analytic process.  
Reflexive positioning 
IPA is underpinned by an epistemological understanding that the researcher plays a key role 
in the analysis of the participants’ data.  This is because the researcher brings to the analysis 
their own beliefs, values and assumptions which may impact on how the data is viewed. In 
line with this is the assumption that researchers will make the analysis more transparent and 
robust.  The chief investigator checked the transcripts with her academic supervisor who 
could highlight when her own assumptions may have been influencing the data.  This was 
potentially the case later in the series of interviews when a pattern of responses was 
emerging.  The early transcription and the iterative nature of the analysis mitigates this. 
Ethics 
Ethical approval was sought from the Health Research Authority and granted in November 
2016.  Application to the appropriate Research and Development (R&D) office was also 
made as the project was being conducted on NHS trust sites.  R&D approval was granted in 
December 2016 (See Section Four: Ethics).  Members of the local transplant forum group, 
including patients who have received ST-VAD as an emergency procedure, provided 
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feedback on the study design and participant information documents.  They felt that the 
interview schedule and information documents were appropriate, however they specifically 
highlighted that they would rather get support from psychologists from the unit rather than 
being provided with contact numbers of support charities.     
Results 
Four superordinate themes were identified during the qualitative exploration of participants 
experiences of ST-VAD.  The descriptions from participants highlighted the nature of the 
journey they had all been on since the emergency procedure.  The superordinate themes were: 
Crisis and the fragile nature of life, “You adapt quite quickly, you’ve got no choice”, Moving 
on, and The Change in Me.  The themes, and sub-themes are summarised below and 
accompanied by quotations from participants.  Figure 2 shows the journey that became 
apparent from the interviews and emergent themes.   
Insert Figure 2. 
Theme 1: Crisis and the fragile nature of life – “it was totally unexpected” (Andy) 
Participants reflected on living well prior to a sudden decline in their health.  Their sudden 
decline in cardiac function was emphasised by the transfer to a specialist Heart Centre and a 
stay within the cardiothoracic critical care unit (CTCCU).  Five participants received 
medication for pre-existing heart conditions and reflected on the rapid and unexpected 
decline in their health .  For example: “I was still active, going away on holiday…doing all 
the sorts of normal things, still in the garden, the dancing and what have you” (John).   For 
the three participants without a pre-existing heart condition, they had no previous difficulties 
regarding their hearts and described “living well” prior to the emergency procedure; for 
example: “I was quite healthy, what I thought of as health…just, normal everyday life 
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…taking [son] swimming, having a shower and stuff like that” (Rose).   These participants 
spoke about being “blue lighted” to their local hospital and transfer to the specialist centre.  
For all participants, even those with managed long-term conditions, the sense of “living well” 
highlighted the enormity of the situation of needing the emergency procedure. The following 
account by Bob illustrates the emergency scenario faced by participants: 
 “I had … an episode at home and we called an ambulance and I was taken through, first to 
[local hospital], then to [regional centre] and at some point, which I can’t remember because I 
was unconscious most of the time, I had a heart attack, heart failure… most of me wasn’t 
working” (Bob).   
Emergency procedure/last resort: “I don’t think there was much choice” (Daisy) 
The ST-VAD was often the last of several interventions that people had received during this 
crisis period before either heart transplant or LT-VAD intervention.  Participants spoke about 
the ST-VAD being the last option to keep them alive; Andy highlights the lack of 
alternatives: “the only alternative was the [ST-VAD], it wasn’t discussed with me what it was, 
cos obviously, I wasn’t in any position to even respond, erm, and I just, slipped away and 
then woke up” (Andy).   
Participants demonstrated a range of understanding in terms of how critically ill each 
had been which appeared to be linked to how long they had been treated with the device.  The 
range of time spent on the ST-VAD ranged from one week to three months.  For those 
participants who were on the ST-VAD for a long time, there was an awareness of the life and 
death nature of their situation while in hospital.  Those who were on the ST-VAD for a few 
weeks were not always aware of how critically ill they had been.  Violet, who had been on 
ST-VAD for one week provided the following account of her experience: 
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“there was one time that got a bit scary, one of [the doctors] told me that actually had I not 
had the [ST-VAD] fitted I wasn’t going to live past that week and then at that point I hadn’t 
known that … I remember feeling emotional after that thinking oh my gosh at that point I 
didn’t even know I was critical” (Violet). 
Participants reflected on the short-term nature of the ST-VAD which provided them 
with only a stop-gap until the next intervention.  Participants spoke about the interventions 
they expected, Tom explained: 
“I was having problems with my kidneys, liver, bowel problems and whatever else…it kind 
of got to the point where it was I needed the [ST-VAD] to kind of keep alive until I could 
have the transplant really” (Tom). 
Ongoing fear of death 
The initial crisis period and the ongoing complications during treatment led to feelings of 
uncertainty for the future for participants.  This fear and uncertainty was further added to by 
concerns regarding the length of ST-VAD use.  Patient’s supported by ST-VAD need to have 
the tubes changed after 30 days which can be a high-risk procedure.  The longer participants 
were on the device, the more likely they would need the tubes changed.  Those who were on 
the ST-VAD within the licensing period were concerned that the clock was ticking and what 
would happen if they reached the 30-day limit. As Violet described: 
 “it was healing things erm but I also was aware that I only had 30 days on it …And that kind 
of scared me as well, and I didn’t know what it meant when this licence expired what would 
happen to me, whether I was still allowed to be on them, whether the tubes would get 
infected, or, whether they would change them, whether after 30 days that was it, but I kind of 
didn’t to want ask” (Violet) 
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Five of the participants were sustained by ST-VAD for a time that exceeded the 
licensing period which meant that tubes needed changing.  This was a daunting procedure for 
participants who were fearful of the outcome.  This highlights the sense of fragility of life 
felt, and the threat of death present, for those on the ST-VAD waiting to be well enough for 
further intervention.  Bob reflected, “only time I got concerned was when they changed the 
[tubes], …, the anticipation of it was worse than the event, erm, but yeah that got me quite 
nervous” (Bob). 
Andy spoke about the physical and emotional side of having tubes changed: 
“It’s horrendous, there’s more people round you, telling you not to worry it’s unbelievable, 
and then what they do is they take the pump out … for that five or six seconds, a quarter of 
your heart doesn’t work so in some cases you get numbness down your face and shortness of 
breath in others there’s pain elsewhere, so it’s an awful experience and, as I said, the worst 
thing was the amount of people around me… it had to be done, so, erm, yeah, just if you want 
to know what the emotions were like, it’s quite scary having that amount of people round 
you” (Andy). 
Geoff relayed in detail the process of the tube changes and his fears during this.  However, he 
felt the authority of the hospital staff helped: 
 “… they put me under the sheet, you know because I was going to be bloody spurting around 
when they changed these tubes. And I thought this is horrendous, and I was really, really 
worried, but with [surgeon], I was under that sheet and I listened to him, and he was saying 
right, you’re doing this you’re doing that and you’re doing the other, and I thought, that’s 
fantastic that, what an air of authority, and [snaps fingers 3 times]and it was over” (Geoff). 
There was a range of reactions to the tube changes, from an engineer who understood the 
changes to others visualising blood spurting everywhere.  Participants were generally calmed 
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by the confidence of the surgeon although the number of people in the room increased 
anxiety.   
Theme 2: “You adapt quite quickly, you’ve got no choice” (Bob) 
This theme encompasses the time that participants were sustained on the ST-VAD. There was 
a sense of moving from a place of shock when first understanding what the machine was, to 
learning to live despite the ST-VAD.  Participants described a love-hate relationship with the 
ST-VAD: the machine was seen as a life saver but also  noisey, causing panic and limiting 
independence and mobility.  They also described complications which would knock 
confidence, and concern regarding the licensing of the machine and what impact this might 
have on them.   
Shock 
Participants reflected on the first time they saw and understood the ST-VAD.  They could not 
always remember being informed about the machine due to the critical physical state they 
were in when the decision was made.  Shock and disbelief were common reactions for 
participants when noticing the ST-VAD. For example:  
“…the moment I woke up, the first thing I thought was Jesus Christ, this is like something 
out of a film, what’s going on” (Andy).  
 “I guess I was just a bit maybe in shock ….  It was only when I started to have physio and 
things and when I got a bit better that it really bothered me, that I was on the [ST-VAD], at 
first I didn’t really, just didn’t really have a concept of how, how like important it was, like I 
understood what it was but the fact that it was like surgically put into my body wasn’t really 
something that I thought about a lot” (Daisy). 
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Participants spoke about the physical impact of being on the ST-VAD and being 
reminded of what the machine was doing when realising that they did not have a pulse: “I 
remember them saying, there’s no point taking her blood pressure because you won’t get 
anything, so I kind of felt like ‘Death Becomes Her’” (Violet).  This highlighted the disbelief 
or unreal nature of being sustained by the ST-VAD in referencing film and fiction rather than 
real life.     
Love/hate relationship: “it was kind of my best mate, it kept me alive” (Geoff) 
Participants moved from the initial sense of shock and disbelief to a love-hate relationship 
with the ST-VAD.  This shift suggested a process of adjustment.  The machine was seen as 
life giving but also very restrictive causing participants to be dependent on others.  They 
often reflected on the role of physiotherapy and their relationship with the ST-VAD.  
Participants spoke of being determined and physiotherapy allowed them to take control to 
work towards becoming fit enough for the next intervention.  However, physiotherapy also 
highlighted the dependence on others, the enormity of the situation and made the ST-VAD 
more real.  Participants were not able to avoid the situation they found themselves in when 
needing to take part in tasks to allow them to get fit for the next intervention. Daisy 
described: 
“I suppose [physiotherapy] just made me more conscious that I was stuck to this machine. 
And it didn’t feel like, oh I’m so glad this machine’s here, I just felt like, this is not fun, you 
know, I really don’t like this” (Daisy). 
Adapting 
There was a sense that participants adapted to the ST-VAD.  John reflected his change in 
perception, “how big and impressive, well not impressive, intimidating it looked the first time 
when you see it, but you soon get used to it” (John).  Participants spoke strongly of being 
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determined to get to the next intervention.  Adapting to the ST-VAD was a step towards 
leaving the hospital.  Some participants noticed feeling physically better while on the ST-
VAD which helped the adaptation, however others struggled with intense pain where the 
machine entered their bodies or constant complications such as infections which made 
adapting more difficult.  Although physiotherapy was a reminder of the enormity of the 
situation, it was also a way to adapt to life with the ST-VAD and a necessity for moving on:  
“for the first five to seven days I was very trepid, I was scared of moving, emotionally etc. 
and then when I got used to it and I started moving, other than the effect that I couldn’t move 
it was good, and feeling as good as I did, made it better, and you know after a week you know 
I was determined I’m going to beat this so right get the physios in” (Andy). 
Participants spoke of life despite the ST-VAD “I just felt a bit of a fraud being there 
[in CTCCU] cos everybody else was in comas and I wasn’t” (Violet). They noted that they 
would be able to sit and talk to friends and family and have jokes with staff members which 
felt different from those in CTCCU who were unconscious. They also spoke about the shock 
of friends and family when first seeing the machine and then that they appeared quite well.  
One participant commented on feeling powerful in that he was living despite the ST-VAD 
and felt proud in front of his friends.   
However, participants struggled with feeling that their illness and treatment was the 
cause of unhappiness and pressure for friends and family.  Participants felt further pressure 
due to the impact the treatment was having on friends and family. One participant noted:  
“I desperately wanted everyone to be happy, I didn’t want to be the one in the middle of it all, 
causing all the fuss, because there was nothing I could do about it, so, that was a really hard 
feeling, I didn’t want anyone else to be upset, in a way I would have felt better if they just 
2-18 
EXPERIENCE OF SHORT-TERM VENTRICULAR ASSIST DEVICE SUPPORT  
 
stayed at home, and just got on with their lives, which they obviously wouldn’t but it was 
hard knowing that I was causing all this” (Daisy). 
Theme 3: Moving On 
Moving on referred to future interventions with the awareness that transplant was the only 
long-term solution.  It was on leaving the hospital that participants started to process the 
seriousness of their critical illness, with memory blanks being filled by hospital staff, friends, 
family and ICU diaries.  Participants also spoke about doing their own research once leaving 
the hospital.   
They saved my life 
Participants reflected on the lifesaving nature of the interventions they had received and were 
grateful for the expertise and support of staff, for example: “I wouldn’t be here today if it 
wasn’t for [the hospital]” (Tom).  Throughout the interviews there was a strong sense that 
friends and family were a source of practical and emotional support, Bob said “friends and 
family … they went above and beyond” (Bob).  Participants said that staff were kind and 
helpful but they felt that their family and friends needed more information and emotional 
support.  Once the ST-VAD was fitted, the support for participants from friends and family 
was bolstered by the hospital staff and support systems such as transplant buddies.  Hospital 
staff offered emotional support and information, encouraging participants to stay positive and 
focus on the next intervention. They enabled participants to voice their fears without 
burdening family or friends. As John described: 
“[staff] tend to fill you in and tell you why things are being done and what this is for and what 
the other’s for so you pick up a lot of information about that… the big difference is they take 
the time to listen to you, to answer your questions and just interact with you as a person” 
(John).  
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Although participants had been determined and striving towards discharge from 
hospital, there was also a sense of loss and grieving as their outpatient appointments became 
less frequent and there was more emphasis on the new heart or LVAD working for itself.  
There was a fine line between those who were still attending the hospital regularly, that this 
was a chore, compared to those who were moving towards six monthly reviews.  The hospital 
and staff became like friends and family for many of the participants.  The participant (Daisy) 
who was three years post discharge felt that she had moved on from that period of her life and 
the sense of loss was not as great.  From this position, participants reflected on the changes 
they had noticed in themselves and that others had noticed in them since the ST-VAD and 
future plans.    
Limbo vs moving on 
Participants were very aware that the ST-VAD was only a short-term solution.  Two 
participants moved on to have an LVAD whereas six had a transplant as the further 
intervention.  None of the participants had recovered sufficient heart function for explantation 
while being on the ST-VAD.  Participants spoke about the need for further intervention to 
enable them to leave hospital.  For example: 
“I was begging for an [LVAD] so I could get out, but it wasn’t worth it for me … yeah you’re 
out of hospital earlier but for me again it would be a stop gap, you know some time in the 
next 2 years I need a heart transplant” (Andy). 
Those on the LVAD had been placed on the transplant list but did not know how long they 
would need to wait,   
“cos I’m doing well, I’m less of a priority than those that are still in hospital or have come 
home but have kind of stayed the same as they were really, I’m less of a priority but still, 
can’t help think, I should be next” (Rose). 
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For some participants, the complications they faced while on the ST-VAD led to a sense of 
relief when they knew they were moving on to a further intervention:   
“… when I knew I was finally getting a transplant, I was just grateful that I wouldn’t have the 
[ST-VAD] in me rather than that I was getting a heart transplant and that was going to save 
my life” (Daisy). 
Moving on from hospital 
Participants spoke about the frequency of outpatient visits to the centre.  This reduced as time 
passed: “Every week we was there, yeah and then it went to every month, once a month and 
now it’s every two months” (Rose).  The hospital appeared to act as a secure base for 
participants who developed a greater sense of autonomy and independence as they had less 
contact with the hospital.  
“I don’t dread going cos there are a bunch of nice people that I’m going to see and stuff and 
you walk down the corridor and there’s always somebody that you know, that I saw when I 
was in the hospital that always says hello and stuff” (Rose). 
Participants who were having less regular contact with the hospital reflected on the 
attachment they had made with the building and the staff.  Violet and Geoff described:  
“it’s weird to say, but I actually miss the hospital sometimes.  When I come here I sometimes 
feel I’m coming home and I know that sounds really strange… I feel like I’m going home 
because to me this was home for so long erm, so I always feel safe coming here … 
everything’s just really nice so I feel like I’m getting support from [psychologist] … and I get 
a lot of support from the nurses” (Violet). 
“it’s almost like a little grieving procedure when they take the [ST-VAD] off you, I’ve got 
one biopsy left and if it goes well, that’s it unless something goes wrong … I’m out there and 
I get on with life, and I think, what do you mean I’m not going back to [hospital], and they 
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said no, no, we will call you in occasionally, once a year for a check-up…but like that little 
sense of where’s my washing machine [ST-VAD] gone, it’ll be like, where’s my visits to the 
hospital gone, it will be a bit of a wrench you know, although I’ll find a way to get back up 
here” (Geoff).  
The participant who was three years post intervention described less attachment to the 
hospital having achieved more autonomy and independence over her health and body,  
“At first I was there every week or even more cos I kept getting ill and I had a couple of 
rejections and stuff but now it’s rare that I go in to [centre],… it’s not a big part of my life” 
(Daisy). 
Theme 4: The Change in Me: “I think my outlook on life has changed, whether 
anybody knows that I don’t know” (Bob). 
Participants reflected on how their outlook on life had changed following the emergency 
intervention, including noticing an inner strength that may not have been evident before.  
This was the case for those with and without pre-existing heart conditions prior to emergency 
implant.  Participants re-evaluated their work-life balance, for example:   
“I was known for going in at six o’clock in the morning, going home 10 o’clock at night and 
then have my tea and back on the laptop again, where now I can get to work at, I’ll get to 
work at 8 o’clock in the morning, I’ll go home at 6, it’s still a reasonably long day for most 
people, … but I go and do that but it’s not kind of working all weekend preparing for 
meetings and travelling down south and here there and everywhere, … , I’ve got more time at 
home, …now we can kind of do more things together and it’s a lot, lot better so, so in that 
respect yeah it has kind of changed but that isn’t a bad thing really” (Tom). 
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Participants also spoke about gaining a different perspective on life and about what 
was really important to them.  Priorities included family and giving back to the hospital either 
via fundraising or being a buddy for future patients, for example:  
 “I think I’ve realised I’m stronger than I thought I was….and a lot more resilient… I’ve got 
more confidence in my ability to deal with things” (Daisy) 
“I feel a lot calmer I don’t know whether that’s going through everything I have, that I have a 
big perspective on life now… one of my work friends has actually said she can see that I have 
changed erm, that I’m a lot calmer, things don’t phase me as much but I also have changed a 
bit in personality” (Violet). 
They also reflected that the journey had brought family close together, “it’s brought [me and 
my wife] closer together, cos she was the only one who was here all the time, for better or 
worse” (Bob). 
Participants noticed that the way other people treated them had changed following the 
emergency procedure. It was often described that their closest family were worried about 
losing them, “The kids all think I’m great, I’m brave, which I’m not. …my wife’s scared of 
losing me” (Andy). 
They reported that sometimes friends and family would be protective over them, “In many 
ways, they still treat you...like a victim of something, you know, they still, they can still be 
ever so careful with you.  As if you cannot cope with something” (Geoff).  However, 
participants would remind those closest to them that they were capable.   They also spoke 
about their friends and family seeing a new strength, “I think they just see me as, just that I 
can get on with things more than maybe it seemed beforehand” (Daisy). 
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Discussion 
This is the first qualitative study to explore the experiences of ST-VAD patients.  Four 
superordinate themes were identified that focused on participants’ journeys from crisis to 
moving on from hospital.  The findings of this study revealed that the initial crisis leading to 
ST-VAD placement continued to impact on participants’ ongoing fear of death, however 
while being sustained by ST-VAD participants learnt to adapt and live despite the device.  
The later themes followed participants as they went on to further intervention and started to 
notice a change in themselves and their priorities following discharge.   
In Abshire and colleagues meta-synthesis regarding adaptation and coping,15  the 
“implantation and hospitalisation” phase highlighted participants high dependency on others.  
In the current study a similar experience was reported while participants were in hospital.  
Participants spoke about their lack of independence while the ST-VAD was implanted.  This 
often related to activities of daily living such as washing and going to the toilet.  
Physiotherapists may be well placed to highlight areas of independence when thinking about 
exercises and emphasising the aspects of daily living they are able and will be able to do as 
they get stronger.  Johnston24 concluded that support was a complex issue when surviving 
critical illness as more support was correlated with increased anxiety.  The key factor that 
was identified was psychological agency and this highlighted better coping.   
Similarly to the Chapman9 study with two ST-VAD participants, the participants in 
the current study reflected on the shock and impact of the ST-VAD experience.  The current 
participants also spoke of the intrusion of the device but this moved to a sense of learning to 
adapt to the device.  Equally, as in Chapman’s “trust” theme, the participants also described 
needing to trust the machinery that was keeping them alive and then to trust their new heart 
or LVAD. 
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In the current study, participants were not always fully aware of the life-saving nature of the 
ST-VAD and this understanding and adjustment was something that happened over time and 
sometimes once discharged.  Chapman9 described those patients who had received ST-VAD 
as an emergency procedure struggling to process what had happened to them.  Waight and 
colleagues25 described the “shock” that patients had on learning they needed coronary artery 
bypass graft surgery was the most traumatic part, either due to being faced with mortality and 
identity crises or learning that they were more ill than they had considered themselves.  This 
is similar to the experience of participants in the current study who were faced with the ST-
VAD which highlighted their own mortality.  This was further emphasised for the 
participants by the 30-day licensing period of ST-VAD.  This study has highlighted a 
potential communication issue for staff, that they should consider the psychological impact of 
licensing issues and how best to communicate this with patients and family.  An approach 
similar to that employed by Dithole26 might be successful.  This would involve “the 
application of augmentative and alternative communication strategies” aimed at helping 
healthcare professionals to make sense and make meaning of the journey on which the patient 
is engaged.  Communication training should also focus on healthcare professionals’ 
knowledge, attitudes and raise self-awareness.27  The training should also help nurses and 
carers to understand the implications of the licensing of the ST-VAD and the reality of facing 
death.  Further to training, healthcare professionals may benefit from ongoing clinical 
supervision regarding communication28 which could be provided by Clinical Psychologists 
attached to cardiothoracic units.  Further research is needed to gain a better understanding of 
the informational and support needs of ST-VAD patients in line with the licensing period. 
Participants spoke of feeling in good hands within the specialist cardiothoracic centre.  
Similarly, Overgaard and colleagues12 described the relief of LVAD participants when they 
arrived at a unit with expert knowledge with it being their “safe haven”.  In the current study, 
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participants described attachments to the hospital and staff which changed over the period of 
time since intervention.  As in the qualitative exploration of experiences of ECMO 
survivors,16 the participants in the current study expressed their thanks to all that had aided 
their recovery and reported gaining new life perspectives. 
Johnston’s24 study regarding surviving critical illness highlighted that participants 
benefited from telling their story which helped to develop a coherent illness narrative for 
what had happened to them.  Indeed, in the current study, participants spoke about making 
sense and “filling in the blanks”; they described gaining information and some brought their 
ICU diaries with them.  Johnston24 proposed that a coherent illness narrative is a necessary 
step for building psychological agency, posttraumatic growth and increased coping.  
Following an understanding of mechanical dependence, participants spoke of adaptation to 
the ST-VAD within hospital.  Participants then moved on to further intervention and with this 
came an awareness of a change in priorities which could be understood as posttraumatic 
growth.  Posttraumatic growth has been defined as “the subjective experience of positive 
psychological change reported by individuals as a result of coping with trauma or highly 
challenging life crises”29 (p1).  These perceived changes include more meaningful 
relationships and changes in personal strength and changed priorities.30  Hefferon and 
colleagues31 reported findings from a systematic review of qualitative studies reporting 
posttraumatic growth and life threatening physical illness.  Along with reappraisal of life and 
priorities, changes in personal strength and more meaningful relationships, there was a unique 
element of posttraumatic growth related to physical illness, that of a new awareness of the 
body which could lead to a better understanding of their body, and changes in health-related 
behaviours.  As in the current study, Hefferon31 described that people report benefits from 
illness while acknowledging the distressing side of the illness.     
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Clinical Implications 
Participants spoke about struggling with anxiety at times and reference was made to 
feeling overwhelmed at times of transition.  This reflected the emergency procedure and 
subsequent treatment as traumatic, being faced with their own mortality, and uncertainty for 
the future.  In the present study, these issues were mostly managed by active problem solving 
and determination to get better or dependence on others for support.  Participants referred to 
receiving information during and post intervention however healthcare professionals may 
need to provide additional emotional support when providing this information and be aware 
that this may need to be discussed during outpatient appointments.  Participants spoke about 
meeting with buddies and felt that this was most effective when they were similar to the 
buddy.  Buddies with experience of the ST-VAD may be well placed to provide normalising 
information and peer support for patients currently being maintained by ST-VAD.   
Although there is little evidence regarding the efficacy of psychological therapies and 
ST-VAD use, Acceptance and Commitment Therapy (ACT) might be appropriate in 
supporting patients during and following ST-VAD implantation.32  The ACT model 
encourages acceptance of a range of experiences, including those which are distressing.  In 
relation to the practice of ACT, clinical interventions focus on the functions of problematic 
thoughts rather than on their content.  This would be particularly relevant to anxious thoughts 
of death in this situation; cognitive approaches would have encouraged challenging such 
thoughts but they would be realistic fears given the need for intensive life support.  ACT 
encourages the use of exercises which aid the identification of personal values which are in 
turn used to identify specific behavioural goals, along with the design and implementation of 
behaviour change strategies to achieve those goals. 32  This values-based work can be 
conducted in acute medical settings and would enable a greater sense of control and more 
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embodied sense of self.  ACT along with other acceptance based approaches such as 
mindfulness33 and Compassion Focused Therapy34 may complement the areas of 
posttraumatic growth that have been apparent in the current research. 
Understanding psychological processes of ST-VAD as an emergency procedure helps 
us to better understand the psychological needs of participants.  From the experiences 
described by participants there are potentially key time points when participants would have 
benefitted from more psychologically informed practice such as transition points, discussing 
licensing issues, living with ST-VAD and trying to have as normal a life as possible.  
Although not the focus of the current research, participants spoke about the emotional support 
needs of friends and family which they felt were limited.  Some participants stated that family 
and friends received psychological support from outside of the unit, however others felt that 
this should be provided by the unit at the most distressing points, for example while the 
patient was unconscious or around the time of transition to transplant or LT-VAD.  Further 
research could include gaining an understanding of the needs of family and friends in this 
situation.   
Participants described an attachment to the hospital and staff members during their 
ST-VAD support and further intervention.  Healthcare staff may benefit from education and 
understanding around the natural attachment process for patients who have survived ST-VAD 
as an emergency procedure.  Specialist units should plan to gradually increase the time 
between appointments not only due to the reducing need for medical intervention but also to 
highlight the psychological benefits of maintaining a safe base whilst patients gain 
psychological agency and confidence in their new heart or LVAD. 
 
2-28 
EXPERIENCE OF SHORT-TERM VENTRICULAR ASSIST DEVICE SUPPORT  
 
Limitations 
The research used a self-selecting sample based on inclusion criteria and a very 
limited sample and as such it may be that these participants had a more positive view of ST-
VAD implantation or life since intervention.  The retrospective nature of participants’ 
accounts might have been influenced by subsequent experiences or outcomes.  This could be 
addressed in future research by following patients through their journey in real time, rather 
than a retrospective study. 
The sample in the study was necessarily small and heterogenous in terms of 
differences in age, gender, previous heart condition, interventions prior to ST-VAD, further 
intervention and place of interview.  Although the common experience was that of ST-VAD 
placement in an emergency it must be acknowledged that the differences between participants 
may have impacted on the experiences.  Further qualitative research may benefit from a more 
defined sampling pool.  
In line with IPA, this study is relatively exploratory and bound by the ST-VAD 
population studied.  Theoretical generalisability can be understood in context with existing 
professional and experiential knowledge.17  Similar investigations with ST-VAD samples 
would be beneficial and contribute to the existing literature.   
Conclusion 
Analysis of interviews identified the importance of navigating a journey from ST-
VAD implantation to further interventions.  Participants acknowledged the distressing aspects 
of the emergency procedure and ST-VAD support; however they also described the positive 
aspects and changed priorities, in line with posttraumatic growth literature. It is hoped that 
the experiences shared by these ST-VAD survivors will help professionals to support adults 
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to live in line with their values in the context of the opportunities and challenges that further 
intervention can bring.   
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What’s New? 
• ST-VAD patients described a journey from the ST-VAD emergency procedure, 
learning to adapt to the machine and moving on to further intervention. 
• Healthcare professionals would benefit from understanding the journey that patients 
travel to further intervention and the attachment they may form with the hospital and 
staff. 
• Participants reflected on positive changes following the emergency procedure which 
may be suggestive of links to post traumatic growth. 
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Figure 1: Flowchart detailing the number of potential participants and final number of participants 
from recruitment centre.  Participants were generally approached at their next outpatient 
appointment when this fell during the recruitment period and as such this had an impact on the 
number of potential participants that were available.  
 
  
Number of patients 
receiving ST-VAD 
intervention between April 
2014- April 2017 
N = 51 
Number of patients 
consenting for the chief 
investigator to contact 
regarding research 
N = 10 
Number of patients 
approached by clinical 
team regarding research 
N = 15 
Number of participants 
who completed 
interviews 
N = 8 
Number of patients who 
met inclusion criteria 
N = 46 
Language, 
communication needs 
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Age Reason for emergency 
procedure 
Time on ST-VAD Time since ST-VAD Further 
intervention 
Andy (M) 52 Deterioration of heart failure 2 months 4 months Heart Transplant 
Bob (M) 57 Heart failure following heart 
attack 
3 months 5 months LVAD 
Daisy (F) 30 Decline following surgery for 
mitrovalve regurge 
2 months 36 months Heart transplant 
Geoff (M) 57 Myocarditis 3 months 19 months Heart Transplant 
John (M) 51 Deterioration of heart failure 3 weeks 1 month Heart transplant 
Rose (F) 38 Spontaneous coronary artery 
dissection 
3 weeks 12 months LVAD 
Tom (M) 38 Deterioration of heart failure 2 months 12 months Heart transplant 
Violet (F) 31 Deterioration of heart failure 1 week 6 months Heart transplant 
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Figure 2. Experiencing ST-VAD: A Journey.  Four superordinate themes and their subthemes related to the short-term ventricular assist device 
journey. 
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Appendix 2-A 
Extract from Geoff’s transcript showing coding for Theme 2 in NVivo. 
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This thesis comprises two main pieces of research, a literature review and an empirical study.  
The literature review addressed the experience of decision-making for patients and caregivers 
regarding the LVAD implant where thematic synthesis of the papers identified three main 
themes of “context”, “mechanism” and “outcome”.  The research paper, an interpretative 
phenomenological analysis (IPA) study, reported the experiences of having a short-term 
ventricular assist device implanted as an emergency procedure.  The participants’ experiences 
were developed into four themes of (1) crisis and the fragile nature of life, (2) “you adapt, 
you’ve got no choice”, (3) moving on, and (4) the change in me.  Conventional reporting of 
research required for the format of this thesis and for publication, limit the depth to which 
these issues can be discussed.  Therefore, this critical appraisal will provide an opportunity 
for further reflection of five areas related to the research.  I will start by discussing the critical 
care environment and existential aspects of VAD followed by my reflections on VADS and 
the research process.  Further to this I describe my professional development and implications 
of working in physical health settings.   Finally, I argue aspects of patient centred care and 
the ethical and legal implications of VAD placement.     
Critical Care Environments and the Existential Aspects of VAD 
The participants who were interviewed in the research paper were cared for in a 
cardiothoracic critical care unit (CTCCU).  Participants in the current study spoke of 
experiences following their CTCCU stay, however the research paper did not focus on the 
Intensive Care Unit (ICU) experiences that are common across conditions or ICU experiences 
such as hallucinations and memory gaps which have been observed in other studies.1-3 Those 
typical ICU experiences were reported by participants and were in line with those often 
spoken about in general ICU research.  There is an awareness of the psychological impact of 
an intensive care stay, such as post-traumatic stress disorder (PTSD), depression and 




to engage with rehabilitation.2  Although there is an increasing awareness of the 
psychological impact of an ICU stay, this is often a medicalised view of PTSD and delirium 
and the causes of these.3 
 The Core Standards for ICU4 highlight the need for a psychological and emotional 
understanding of patients’ needs, however, this is not clearly defined.  It is suggested that 
psychologists should be part of the multi-professional team that conduct delirium assessments 
and provide strategies and interventions.  Within the more recent Guidelines for the Provision 
of Intensive Care Services5 it is recommended that psychological input is offered both within 
and following ICU stay.  
With a better understanding of the need for psychological support during and after 
ICU stay, thought needs be given to the role that a clinical psychologist might have.  It has 
been suggested that the role of clinical psychology is to give patients space for discussing and 
sharing their experiences.6 Characteristic themes that can be discussed are survival, lost time 
and ICU experiences.  Survival can be understood in two ways: 1) survival from death, and 2) 
survival for life.6  The factors that lead people to an ICU stay mean that patients have often 
been close to death and therefore confronted with their own mortality.  Participants in the 
research paper reflected that “it was not my time” and “there was a reason why I didn’t go 
then”.  Clinical psychologists are well placed to speak about death, beliefs, experiences and 
assumptions.   
Confrontation with mortality can change an individual’s world view, how they see 
themselves and how they see others.7  In the situation of VAD support, the patient realises the 
existential threat to themselves and that a machine controls his/her life.  For those who have 
VAD implanted as a bridge to transplant, they describe themes of dependence on a 




therefore waiting for someone else to die.7  With this in mind, people maintained by VAD 
need psychological support as they can experience psychosocial and emotional stress as 
severe as those following heart transplant.  It has been suggested that social support is a key 
element for positive outcomes.  In discussion with my field supervisor, a Clinical 
Psychologist within a Cardiothoracic Unit, it was pointed out that LVAD placement can 
affect transplant in that the LVAD can stabilise a patient and they would not be classed as 
high priority.  This was highlighted in the research paper by participants supported by the 
LVAD and also in the thematic synthesis.  My field supervisor described that there have been 
cases in the UK where people have sabotaged their LVAD so that they can be admitted to 
CTCCU and urgently listed for heart transplant.   This emphasises the need for clear 
information regarding the impact of the decision to have LVAD implantation.  Furthermore, 
as the complexity of distressing factors increases for individuals so does the emotional 
burden, which highlights the need for healthcare teams to understand the background and 
future treatment plans for each patient.  
Research has described an often raised question by ICU survivors of “why me?”.6  
This uncertainty could be understood for all participants in the research paper, those who had 
no previous heart conditions but also for those who had been taking care of themselves in 
light of heart failure.  Uncertainty in illness happens when “a person is unable to structure 
meaning in illness-related events”8 (p72).  Understandably, patients may struggle with 
questions such as “will there be a complication?” or “how quickly will I deteriorate?”.  It has 
been suggested that for patients considering long-term mechanical circulatory support 
(LVAD) “perhaps one of the most important elements in clinical encounters is helping the 
patient to recognise that uncertainty persists in modern medicine”9 (p185).   
As described in the research paper, a coherent illness narrative is necessary after 




diary.  During the interviews in the research study, participants gave varied responses 
regarding the helpfulness of their ICU diary.  Some participants had brought their diaries to 
show me whereas others had not yet received theirs.  For those waiting to receive their dairy, 
there was a sense of uneasiness as to what it would say and they felt that they had to rely on 
information from family, friends and the medical team for “filling in the blanks”.  One 
participant spoke about going through their medical notes with the clinical psychologist as 
they felt that the diary was more about what the inpatient stay was like for her family, she felt 
that she missed chunks of real world news and what had happened to her.  This suggests that 
she was searching to build a coherent illness narrative.  The theme of “time had got lost” has 
been reported elsewhere.6  As participants did not receive their diaries until they were 
attending outpatient clinics, it was sometimes difficult for them to piece together what had 
happened to them.  One participant spoke about a telephone call with a friend who imparted 
some important world news, and she thought her friend was joking as she was not aware of 
this news due to being unconscious; this highlighted to her the time that she had missed from 
the world.  A clear illness narrative has been linked to posttraumatic growth and effective 
coping10 and therefore it is important to understand how best to collect and deliver “the 
missing blanks”.  Healthcare professionals need to keep in mind that not all patients will want 
all of the information and that this discussion needs to be had so that information can be 
tailored to what the individual wants.   
My Reflections on VADs and the Research Process 
As I have written this thesis, and as I write this, it is apparent to me that as a healthy woman 
with no first-hand experience of what the participants have gone through I have been made 
more conscious of the total ‘otherness’ of their experience.  In terms of my position on heart 
failure and the use of ventricular assist devices I would describe myself as somewhat naive as 




led to participants providing rich descriptions, explanations and information about their 
experiences.  However, as a young female asking questions of older men this may have 
impacted on the topics that were discussed in this study.  My closeness in age to the female 
participants highlighted to me the critical nature of the situations that led to their emergency 
procedures.  It was further highlighted to me that this experience could happen to anyone, 
including myself.  I find this very humbling and feel that I am a more empathic listener 
within the interviews and my day to day work.   
While arranging and conducting the interviews, I was often struck by the realities of 
living with an LVAD or life following transplant.  One participant let me hold her VAD bag, 
which contained the power source and controller and I became more aware of the intrusion 
this had on her life.  There was also a strong narrative throughout the interviews of the on-
going ups and downs and complications that were evident once people had been discharged 
from the CTCCU.  At times I felt a tension between the research role I was in and my 
everyday clinical role.  When participants became upset it was difficult not to be drawn 
towards a more clinical role.  This highlighted the sometimes challenging nature of 
conducting research as a clinician and the need for clear protocols.  During the research 
process, I was able to balance this by reminding myself of my role at that time and ensuring I 
debriefed each participant fully, reminding them of the support available to them.      
Further, the majority of interviews were conducted within the specialist unit, and this 
context may have given emphasis to certain issues such as healthcare professionals practice.  
This environment may also have had an impact on how participants saw themselves in terms 
of health and illness.  Responses may have been different in environments where they were 
not labelled “patients”.  During the research process I kept a reflective diary, which was 
useful during the analysis using my notes on initial hunches and my thought process 




diary provided a space for my reflections, which is required in interpretative 
phenomenological analysis to prevent preconceptions from unduly influencing the analysis 
process.   
Professional Development and implications for working in physical health settings 
My interest in health psychology started prior to clinical training.  My first memory of the 
impact of critical illness was the death of my sister’s best friend following kidney transplant 
aged 10. I was 7 years old at the time.  My recollection was of how ill she was leading up to 
transplant and the hope that those around her had when a match was found. She died shortly 
after the surgery.  Subsequently, I felt the impact of the psychological needs of the people 
with acute and chronic illness and the impact on their parents, carers and those around them.  
I have often been drawn to the phrase “extraordinary things happening to ordinary people”.  I 
feel this is often the case within a physical health field where traumatic and life changing 
events can happen to anyone.  I completed a Masters degree in Health Psychology prior to 
clinical training and learnt about the models related to health psychology and developed my 
understanding of how we understand the experiences of health and illness.  During clinical 
training, I have sought placements within healthcare settings with both adults and children 
and have completed research into healthcare professionals’ understandings of clinical 
psychology within the ICU as part of a small-scale research project.  During my specialist 
placement I worked on a paediatric oncology unit and was further struck by the fragile nature 
of life and the benefits of hearing people’s stories and enabling people to tell their stories.  
These experiences have reinforced the value of clinical health psychology that I had 
developed and have promoted a wish to support people coping with the challenging and 




A recognition of the importance of psychosocial outcomes has begun to filter into 
different specialties within the physical health field.  The Faculty of Clinical Health 
Psychology within the British Psychological Society11 produced a briefing paper to provide 
information regarding the role of clinical health psychologists and how such professionals 
can fit into current health systems.  This role can include: direct work, working with teams, 
providing support and supervision to staff and involvement with research and evaluation.11  It 
is suggested that clinical psychologists within a health setting are well placed to integrate 
physiological, emotional, cognitive, behavioural, interpersonal and socio-cultural factors and 
understand the impact that these factors may have on an individual and how they might 
influence adjustment or recovery.12  Furthermore, clinical psychologists are well placed to 
communicate this information to teams.   
Patient-Centred Care 
In a medically dominated field, I have often witnessed the physical aspects of healthcare 
being given priority and patient experiences being overlooked.  However, in the thematic 
synthesis there were signs that the patient and caregivers’ voices were given volume by 
healthcare professionals.  Supporting the voices of patients to be heard through qualitative 
research, as well as synthesising the findings of such research, aids in giving more dominance 
to the patients’ voice.  Over the last two decades there has been a move towards a more 
patient/person centred health service.  As reported by The King’s Fund13 patients need to be 
engaged and involved in decisions about their care, which can be facilitated by ensuring they 
are given the opportunity, information and support to do this.  It is also stated that services 
are to reflect the needs of their patients.  For this to be achieved, patients and caregivers need 
to be involved in all aspects of health care services including, commissioning, planning, 




In terms of patient-centred decision-making, it has been highlighted that there is a 
need for healthcare professionals to contribute their expertise and support patients to use that 
expertise to inform their decision.14  Furthermore, it has been reported that patient 
involvement with decisions improves outcomes.14  Schwartz and colleagues15 described that 
in their experience of decision-making they felt emotionally and cognitively overwhelmed 
when faced with a new reality.  It was reported that this impacted on taking in and processing 
the information regarding healthcare related decisions.  This provides strength to the 
argument of tailoring communication to the individual and re-visiting information throughout 
the timeline of decision-making.  
The empirical study was developed during discussions with the field supervisor for 
the project, a clinician working within the Cardiothoracic Unit.  This helped to ground the 
research in the clinical setting.  Furthermore, it highlighted the under researched area of the 
ST-VAD.  During the design of the research project, Transplant Buddies were involved by 
providing feedback regarding the design, practicalities and recruitment documentation.  This 
was an invaluable perspective for me as someone new to the area of VADs.  Following 
interviews, participants were offered a copy of the transcript to comment on.  The aim was to 
ensure that I had understood what had been described.  However, only two participants 
accepted this and although copies were sent I did not receive any feedback.  On reflection I 
wonder if the participants who agreed to a copy of the transcript have used this as a way to 
develop a coherent illness narrative.  In the future I would consider other ways to facilitate 
this feedback.  Schwartz and colleagues15 discussed the importance of involving patients in 
research from the design to analysis and write up.  It is believed that this enables research to 
be more clinically relevant, genuine and in the interest of patients and services rather than 




was difficult due to the small numbers of patients who experience the ST-VAD and the 
impact this would then have had on those I was able to recruit for the study.  
 
Ethical and Legal Implications of VAD placement 
From the research paper there is evidence that posttraumatic growth was present for 
participants.  However, research has stated that partners/caregivers may be more likely to 
struggle with post-traumatic stress disorder type symptoms following VAD.16  This was 
described by some participants in the research paper.  Services need to consider how best to 
support families within the confines of commissioning structures.   
For those caregivers of patients with LVAD who are bereaved, research describes 
high levels of confusion at the end of life.17   More research and understanding is needed 
regarding the educational processes, timing and reiteration of information.  Confusion at the 
end of life for an LVAD patient includes lack of knowledge about the nature of death, about 
the medical decisions to be made and about the palliative care and hospice services provided.  
The ethical and legal issues of LVAD deactivation can be a source of  contention.18-20  
Commentaries from the USA suggest that VAD discontinuation can be seen as ethically 
permissible if this treatment is no longer consistent with the patient’s goal, often increased 
quality of life, however, clinicians may have differing attitudes towards this and view 
deactivation as euthanasia.20  In discussion with my field supervisor she has described that 
the legal advice provided to the Cardiothoracic Unit depends upon whether the device is 
mostly external or internal to the body as to whether deactivation is classed as euthanasia or 
allowing a patient to die from advanced heart failure.   Published work from the USA argues 
that other percutaneous interventions are understood as distinct from the body.18,19 Further 




arise.18,19   The inclusion of ethics panels and palliative care teams can support deactivation 
decisions.17,21 
Within emergency situations, consideration needs to be given to presumed and 
surrogate consent.22  This begs the question of whether it is ethical to implant a mechanical 
device such as a VAD.  This highlights the need for advanced directives or preparedness 
planning,20 especially in understanding the wishes of those with heart failure.  Advanced 
directives need to be revisited over time to allow for changes.  Presumed or surrogate consent 
can lead to distress and regret, as seen in the thematic synthesis with thoughts such as “did I 
do the right thing?”  This is more difficult for those who are supported by VAD where the 
heart condition came “out of the blue”.  The ethical and legal aspects of VAD placement need 
to be further understood and perspectives from other countries taken into account.  
Summary 
In summary, this critical appraisal has focused on the critical care environment, existential 
aspects of VAD, my reflections on VAD and the research process.  I went on to describe my 
professional development, the role of clinical psychologists in physical health settings and the 
importance of patient centred care.  Finally, I suggested further clinical implications 
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Ms Eleanor Taylor 
Trainee Clinical Psychologist  
Lancashire Care NHS Foundation Trust 
Division of Health Research 
Furness Building  
Lancaster University  
LA1 4YG 
 
07 November 2016 
 
 
Dear Ms Taylor 
 
 
Letter of HRA Approval 
  
Study title: What are the experiences of people following short term VAD 
implant as an emergency procedure 
IRAS project ID: 205179 
REC reference: 16/NW/0631 
Sponsor Lancaster University 
 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, 
on the basis described in the application form, protocol, supporting documentation and any 
clarifications noted in this letter. 
 
 
Participation of NHS Organisations in England 




Appendix B provides important information for sponsors and participating NHS organisations 
in England for arranging and confirming capacity and capability. Please read Appendix B 
carefully, in particular the following sections: 
• Participating NHS organisations in England – this clarifies the types of 
participating organisations in the study and whether or not all organisations will be 
undertaking the same activities 
• Confirmation of capacity and capability - this confirms whether or not each type of 
participating NHS organisation in England is expected to give formal confirmation 
of capacity and capability. Where formal confirmation is not expected, the section 
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also provides details on the time limit given to participating organisations to opt 
out of the study, or request additional time, before their participation is assumed. 
• Allocation of responsibilities and rights are agreed and documented (4.1 of HRA 
assessment criteria) - this provides detail on the form of agreement to be used in 
the study to confirm capacity and capability, where applicable. 
 
Further information on funding, HR processes, and compliance with HRA criteria and 
standards is also provided. 
 
It is critical that you involve both the research management function (e.g. R&D office) 
supporting each organisation and the local research team (where there is one) in setting 
up your study. Contact details and further information about working with the research 
management function for each organisation can be accessed from www.hra.nhs.uk/hra-
approval. 
Appendices 
The HRA Approval letter contains the following appendices: 
• A – List of documents reviewed during HRA assessment 
• B – Summary of HRA assessment 
 
After HRA Approval 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with 
your REC favourable opinion, gives detailed guidance on reporting expectations for studies, 
including: 
• Registration of research 
• Notifying amendments 
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, and is updated in the light of 
changes in reporting expectations or procedures. 
 
In addition to the guidance in the above, please note the following: 
• HRA Approval applies for the duration of your REC favourable opinion, 
unless otherwise notified in writing by the HRA. 
• Substantial amendments should be submitted directly to the Research Ethics 
Committee, as detailed in the After Ethical Review document. Non-substantial 
amendments should be submitted for review by the HRA using the form 
provided on the HRA website, and emailed to  hra.amendments@nhs.net. 
• The HRA will categorise amendments (substantial and non-substantial) and issue 
confirmation of continued HRA Approval. Further details can be found on the HRA website. 
 
Scope 
HRA Approval provides an approval for research involving patients or staff in NHS 
organisations in England. 
 
 
If your study involves NHS organisations in other countries in the UK, please contact the 
relevant national coordinating functions for support and advice. Further information can be 
found at  http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/. 
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If there are participating non-NHS organisations, local agreement should be obtained in 
accordance with the procedures of the local participating non-NHS organisation. 
 
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please email the HRA 
at hra.approval@nhs.net. Additionally, one of our staff would be happy to call and discuss 
your experience of HRA Approval. 
 
HRA Training 
We are pleased to welcome researchers and research management staff at our training days 
– see details at http://www.hra.nhs.uk/hra-training/ 
 








Copy to: Dr Diane Hopkins- Sponsor contact 
Lindsay Murray, University Hospital of South Manchester NHS Foundation 
Trust 
– R&D contact 
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Appendix A - List of Documents 
 
The final document set assessed and approved by HRA Approval is listed below. 
 
Document Version Date 
Copies of advertisement materials for research participants 
[Poster] 
2 27 September 
2016 Evidence of Sponsor insurance or indemnity (non NHS 
Sponsors only) [Insurance Document] 
  
Interview schedules or topic guides for participants [interview 
schedule] 
1 01 June 2016 
IRAS Application Form [IRAS_Form_04082016]  04 August 2016 
IRAS Application Form XML file [IRAS_Form_04082016]  04 August 2016 
Letter from sponsor [IRAS sponsorship letter]   
Other [Staff information sheet] 1 01 June 2016 
Other [Participant expression of interest form] 1 01 June 2016 
Other [Participant debrief sheet] 1 01 June 2016 
Other [Insurance Document professional negligence]   
Other [Participant Follow up letter] 1 27 September 
2016 Other [HRA SoE] 1 25 October 2016 
Other [HRA SoA] 1 25 October 2016 
Participant consent form [Consent form] 3 03 November 
2016 Participant information sheet (PIS) [PIS] 3 03 November 
2016 Research protocol or project proposal [STVAD protocol] 1 01 June 2016 
Summary CV for Chief Investigator (CI) [Chief investigator CV] 1 01 June 2016 
Summary CV for supervisor (student research) [supervisor CV]   
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Appendix B - Summary of HRA Assessment 
 
This appendix provides assurance to you, the sponsor and the NHS in England that the 
study, as reviewed for HRA Approval, is compliant with relevant standards. It also provides 
information and clarification, where appropriate, to participating NHS organisations in 
England to assist in assessing and arranging capacity and capability. 
 
For information on how the sponsor should be working with participating NHS 
organisations in England, please refer to the, participating NHS organisations, 
capacity and capability and  Allocation of responsibilities and rights are agreed and 
documented (4.1 of HRA assessment criteria) sections in this appendix. 
 
The following person is the sponsor contact for the purpose of addressing participating 
organisation questions relating to the study: 
 




HRA assessment criteria 
 
Section HRA Assessment Criteria Compliant with 
Standards 
      Comments 
1.1 IRAS application completed 
correctly 
Yes No comments 
    
2.1 Participant information/consent 
documents and consent process 
Yes No comments 
    
3.1 Protocol assessment Yes No comments 
    
4.1 Allocation of responsibilities and 
rights are agreed and 
documented 
Yes Statement of activities will act 
as an agreement of an NHS 
organisation to participate. 
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Yes Where applicable, independent 
contractors (e.g. General Practitioners) 
should ensure that the professional 
indemnity provided by their medical 
defence organisation covers the 
activities expected of them for this 
research study 
4.3 Financial arrangements 
assessed 
Yes No application for external funding has 
been made. 
    
5.1 Compliance with the Data 
Protection Act and data 
security issues assessed 
Yes No comments 
5.2 CTIMPS – Arrangements for 
compliance with the Clinical 
Trials Regulations assessed 
Not Applicable No comments 
5.3 Compliance with any 
applicable laws or regulations 
Yes No comments 
    
6.1 NHS Research Ethics 
Committee favourable opinion 
received for applicable studies 
Yes No comments 
6.2 CTIMPS – Clinical Trials 
Authorisation (CTA) letter 
received 
Not Applicable No comments 
6.3 Devices – MHRA notice of no 
objection received 
Not Applicable No comments 
6.4 Other regulatory approvals 
and authorisations received 
Not Applicable No comments 
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Participating NHS Organisations in England 
 
This provides detail on the types of participating NHS organisations in the study and a 
statement as to whether the activities at all organisations are the same or different. 
 
This is a single NHS site study. The study activities will be undertaken by the research team 
once the eligible participants have been identified by the clinical care team. 
 
The Chief Investigator or sponsor should share relevant study documents with participating 
NHS organisations in England in order to put arrangements in place to deliver the study. The 
documents should be sent to both the local study team, where applicable, and the office 
providing the research management function at the participating organisation. For NIHR CRN 
Portfolio studies, the Local LCRN contact should also be copied into this correspondence.  
For further guidance on working with participating NHS organisations please see the HRA 
website. 
 
If chief investigators, sponsors or principal investigators are asked to complete site level 
forms for participating NHS organisations in England which are not provided in IRAS or on 
the HRA website, the chief investigator, sponsor or principal investigator should notify the 
HRA immediately at  hra.approval@nhs.net. The HRA will work with these organisations to 
achieve a consistent approach to information provision. 
 
 
Confirmation of Capacity and Capability 
 
This describes whether formal confirmation of capacity and capability is expected from 
participating NHS organisations in England. 
Participating NHS organisations in England will be expected to formally confirm their 
capacity and capability to host this research. 
• Following issue of this letter, participating NHS organisations in England may now 
confirm to the sponsor their capacity and capability to host this research, when ready 
to do so. How capacity and capacity will be confirmed is detailed in the Allocation of 
responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) section of this appendix. 
• The Assessing, Arranging, and Confirming document on the HRA website provides 
further information for the sponsor and NHS organisations on assessing, arranging 
and confirming capacity and capability. 
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• Principal Investigator Suitability 
 
This confirms whether the sponsor position on whether a PI, LC or neither should be in place 
is correct for each type of participating NHS organisation in England and the minimum 
expectations for education, training and experience that PIs should meet (where applicable). 
 
A Local Collaborator to be allocated at the participating NHS Trust. 
 




HR Good Practice Resource Pack Expectations 
 
This confirms the HR Good Practice Resource Pack expectations for the study and the 
pre-engagement checks that should and should not be undertaken 
Use of identifiable patient records held by an NHS organisation to identify potential 
participants should be undertaken by a member of the direct care team for the patient, so it 
would not normally be acceptable for this to be done by staff not employed by that 
organisation. A Letter of Access would be expected for any external NHS/HEI staff 
undertaking all of the other activities for the study once consent from the participant is in 
place. The pre-engagement checks should include an enhanced DBS check and 




Other Information to Aid Study Set-up 
 
This details any other information that may be helpful to sponsors and participating NHS 
organisations in England to aid study set-up. 
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A ventricular assist device (V) is a mechanical pump that is used to support heart function and 
blood flow for people who have weakened hearts.  The device takes blood from a lower chamber of 
the heart and helps pump it to the body and vital organs, just as a healthy heart would (The National 
Heart, Lung and Blood Institute, n.d.).  It does not completely replace the heart but the VAD works 
with the heart to help it pump more blood with less work.   
The VAD may be used to support and stabilise the heart until a suitable donor heart can be 
found for transplantation; this is called bridging to transplantation (BTT).  The VAD can also be used 
to support a heart to allow it to return to strength after an acute illness; this is called bridging to 
recovery (BTR). The NHS currently commissions the use of VADs as a Bridge to Transplant or a 
Bridge to Recovery (NHS England, 2013).  Specific VADs may also be used as a Bridge to Decision 
(BTD) which can act as a temporary measure to stabilise the heart prior to decisions regarding 
transplant or a similar intervention.   
There are broadly two types of VAD, “short term VAD” and “durable/long term VAD” 
depending on the nature of the device.  Durable/long term VAD enable patients to be discharged from 
hospital as some of the device is implanted within the body.  There is a cable that shows outside the 
body which connects the pump to a controller and power source which is worn outside the body.  
Previous research has focused on the experiences of patients with a durable/long term VAD 
implanted.  These studies have reported that patients who temporarily or permanently rely on VADs 
for end stage heart failure may face complex psychological, emotional and relational problems 
(Modica, Ferrantini, Torri, Oliva, Martinelli, De Maria & Frigerio, 2014).   
A literature review was conducted by MacIver and Ross (2012) regarding quality of life for 
individuals with VAD.  Durable/long term VAD clinical trials suggest improvements in quality of life 
are seen from 1-3 months post implant; however emotional distress is often unexplored within these 
trials (McIver & Ross, 2012).   Furthermore, qualitative research has explored the impact of VADs on 
patients and their lives, quality of life during and after VAD support, perceptions and concerns of 
patients and care givers and psychosocial and sexual concerns (e.g. Chapman, Parameshwar, Jenkins, 
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Large & Tsui, 2007).  These studies report themes of the journey of adjusting to the device (Casida, 
Marcuccilli, Peters & Wright, 2011), mechanical dependence for life (Marcuccilli, Casida & Peters, 
2013; Overgaard, Kjeldgaard & Egerod, 2012) and perceived control over their lives (Hallas, Banner 
& Wray, 2009; Zambrowski, Combs, Cronin & Pfeffer, 2009). 
The short term VAD is an external cardiac device that means people are maintained in 
intensive care; long term devices are internal and thus patients can be discharged home.  Short term 
devices offer temporary circulatory support with the aim to temporarily stabilise patients with acute 
cardiogenic shock, with the aim to rest the heart (Subramaniam, 2015); this allows time to understand 
what intervention a person would benefit from.  Short-term VADs (ST-VAD) therefore offer a bridge 
to decision (BTD) regarding the most useful intervention, which can include a later exchange to 
implantable/durable VAD,  or removal for myocardial recovery and heart transplant (Takayama, 
Takeda, Doshi & Jorde, 2014).   Takayama, Truby, Takeda and Naka (2014) point out that there is no 
clear definition of “short-term VAD”, however, in line with the definition used by them, the current 
research will define “short-term VAD as mechanical circulatory support devices used only in the in-
patient treatment setting” (p.2).  This study will be focussing on the experiences of people who have 
undergone ST-VAD as an emergency procedure. 
The research above focused on those with durable/ long term VAD, however a study by 
Chapman, Parameshwar, Jenkins, Large and Tsui (2007) conducted an interpretative 
phenomenological analysis pilot study with both durable/ long term VAD (4 patients) and ST-VAD (2 
patients) patients. The two ST-VAD patients had received VAD as an emergency procedure.  
Chapman et al (2007) commented on the intrusion and adverse effects of the device, the impact of 
implanting the VAD as an emergency procedure, the difficulty to adapt after surgery and the lack of 
time to prepare family members who were shocked by the device when they first saw it.  Furthermore, 
Chapman et al (2007) highlighted that different devices, durable/ long term or short term, may 
produce different experiences but due to the small sample size of ST-VAD within the Chapman et al 
(2007) it cannot be said whether the external VAD had a greater impact.  As described, research tends 
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to focus on the impact for people with durable/long term VAD which may be a different experience 
from those who have a short-term VAD.  ST-VADs are different to durable VADs.  Short term VADs 
have external pumps and the patients mobility is severely limited and patients have intensive nursing 
support within a critical care environment.  The ST-VAD offers critically “ill” patients a bridge to 
decision.  Research has been conducted into the quality of life and experiences of people who have a 
durable/long term VAD often as a bridge to transplant, bridge to recovery or destination therapy 
however, little research has focused on the experience and psychological impact of short term VAD 
implant. 
Service requirements for centres providing VAD allow centres to configure teams in a 
flexible manner to best serve the patients, however it is highlighted that social and psychological 
support should be available to patients and their families (NHS England, 2013).  A deeper 
understanding of the experiences of people who undergo short term VAD treatment as an emergency 
procedure would be beneficial for all working with this group of people.  Due to the training and 
knowledge of clinical psychologists, they are well placed to disseminate such knowledge and aid 
other multidisciplinary teams and individuals around the psychological reactions to such 
interventions. 
Aim 
The current research aims examine the lived experiences of people following ST-VAD 
implant as an emergency procedure.  Therefore, this research will obtain subjective accounts of the 
experience of adults who have undergone ST-VAD implant and through their transition to further 
intervention to inform the potential role of clinical psychologists in their post-treatment care.   
  




A qualitative approach to data collection and analysis will be adopted, employing face-to-face 
interviews.  Telephone or Skype interviews may be used to enable participants to be included in the 
study.  A semi-structured interview schedule (Appendix A) will be used to promote discussion on the 
subject of the research aims including basic demographic information , details of treatment, the 
journey to receiving ST-VAD, experiences during ST-VAD support, transition to further intervention 
and expectations for the future.    This schedule will also allow flexibility and be responsive in order 
to facilitate participants in sharing their individual experiences and views.   Following the first 
interview, the academic supervisor will read the transcript and will discuss this with the chief 
investigator in order to consider changes to interview style or order of questions.   
Data will be analysed using Interpretative Phenomenological Analysis (IPA) as this approach 
aims to “explore in detail individual personal and lived experiences and to examine how participants 
are making sense of their personal and social worlds” (Smith & Eatough, 2007, p.36).   Rather than 
applying predefined categories, this approach allows for expression of the lived experience through 
analysis which encourages the researcher to focus on contexts and perspectives of individuals as well 
as a group.  Furthermore, this approach recognises the role of the researcher as an interpretative 
resource and the sense-making of people’s accounts by the researcher during the analysis (Smith, 
Flowers & Larkin, 2009). 
Materials  
Potential participants will be provided with a participant information pack (Appendix B).  
This will include a participant information sheet and an expression of interest form including 
information on how to contact the researcher to obtain further information or to register interest in 
taking part in the study.  A staff information sheet (Appendix C) will be provided for staff who will be 
handing out the information regarding the project to potential participants.  Participants will be asked 
to complete a consent form (Appendix D) prior to the interview commencing.  A semi-structured 
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will be recorded using a digital recording device.   
Participants 
Participants will be recruited from the Cardiothoracic transplant unit of a hospital in the North 
West of England with the potential for further participants to be recruited from fellow cardiothoracic 
units within the UK.  Between eight to twelve participants will be interviewed.  Participants will be 
people who have had a short term VAD (ST-VAD) as an emergency procedure and been discharged 
from ICU to outpatient treatment.  The study aims to gather people’s experience across the timeline 
following ST-VAD. Tentative figures from the unit suggest that approximately 10-15 people per year 
fit these criteria at  and numbers are increasing each year.  Inclusion criteria are:  
1) People who have undergone ST-VAD as an emergency procedure
2) People discharged from ICU and therefore outpatients.
3) People who have capacity to give consent.
Participants who do not speak English or have special communication needs will be excluded from 
the study because there are no financial resources to allow for the use of interpreters.  In addition, the 
method of analysis relies on the accurate use of words by participants and therefore would be likely to 
become more unreliable when based on interpreted accounts.   
It is hoped that between 8-12 participants who meet the inclusion criteria will be recruited to 
the study, which would provide enough data to allow for the development of similarities between the 
accounts without the individuality and differences being lost (Smith, Flowers & Larkin, 2009).    
Recruitment 
Participants will be recruited by members of the cardiothoracic team (e.g. specialist 
nurse/consultant cardiologist/psychologist).   Clinicians will distribute information packs to those 
patients who fit the criteria and who express an interest.  Participant information packs will be either 
given to potential participants when attending for regular outpatient appointments, or posted to 
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potential participants if they are not due in outpatient appointments during the next 3 months.  
Furthermore, potential participants will be informed of the research via telephone calls made by 
known health care workers.  Participants can contact the chief investigator directly to ask questions 
about the research.  Alternatively those patients who opt in to the research via the clinician 
responsible will be informed that they can request to be contacted directly by the chief investigator so 
as to retain anonymity.  Posters will also be displayed in the cardiothoracic department (Appendix E).   
The research will be outlined to the team members, with opportunity for them to ask questions 
regarding the study.  They will also be given a staff information sheet regarding the process of sharing 
the participant information packs, to ensure that this will be conducted in a facilitative rather than 
coercive manner (Appendix C).  The participant information packs will be provided to members of 
staff for example, specialist nurse/consultant cardiologist/psychologist, to distribute to potential 
participants.  The staff member will ask the participant whether they would agree to sign an 
expression of interest/consent to contact form, providing a contact telephone number, to allow the 
chief investigator to contact the potential participant to provide further information regarding the 
study.  The expression of interest form (Appendix F) can be collected by the healthcare professional 
to pass on the researcher.  The potential participant will also be provided with a stamped addressed 
envelope in which to request further information or to register their wish to take part in the study 
which can be used to maintain their anonymity of participation.   
The participant information sheet will state that participation in the study is voluntary and that 
confidentiality will be maintained, unless there is indication of either risk to self or others.  It may be 
possible for the chief investigator to attend follow up clinics when it is known that ex short-term VAD 
patients will be attending.  Participants who have registered interest in taking part in the study will be 
contacted to arrange a time and location that is mutually convenient for the interview to take place.   
Procedure 
Interviews will be able to take place in a room at the transplant unit or at the participants’ 
home.  If a room at the transplant unit is used then it will be booked in the chief investigator’s name 
so as to ensure anonymity for the participant.  The chief investigator will remain aware of personal 
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safety and follow lone worker policies when conducting interviews in line with Lancaster University 
guidance.  
At the outset of the interview, the nature and purpose of the research will be outlined to the 
participant. The chief investigator will also clarify their role in relation to the transplant team and the 
research and confidentiality and its limits will be reiterated. Subsequently, the participant will be 
asked to sign the consent form (Appendix D).  Interviews will last approximately one hour, which 
could be split across two sessions if the participant wishes. The interview will be recorded using a 
digital recorder.  
At the end of the interview, the participants will be asked whether they wish to be contacted at 
the conclusion of the research in order to receive an outline of the results, on which they will be 
invited to comment.  These comments will not be used to alter the interpretation of the data, but will 
be included in the final report where relevant.  They will also be asked whether they would like to 
choose a pseudonym, to be used to refer to their quotations, in the write up on the research.  If the 
participant does not wish to do so, they will be informed that the chief investigator will assign a 
pseudonym.  The recorded interviews will be transcribed and all identifying information (eg names 
and places) will be removed from the transcriptions. The digital recordings will be deleted after 
transcription.   
Practical Issues 
It will be important that participants are able to contact the chief investigator to ask any 
questions they may have about taking part in the research.  The university will be able to furnish the 
chief investigator with a mobile telephone in order to receive texts and calls from participants.   
Where travel expenses are incurred by participants, these will be reimbursed, up to £20, by 
the university.   
Other financial implications of the research will include printing, photocopying and postage of 
materials, including participant and staff information sheets and consent forms.  These costs will be 
met by the university.   
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Ethical considerations 
There are two principle ethical concerns regarding potential participants: ensuring anonymity 
of participants and the potential for distress amongst participants.  Furthermore, the procedure for lone 
working for the chief investigator. 
Lone worker 
Interviews may take place in participants’ homes.  If this occurs, a buddy system will be in 
place.  A peer clinical psychology trainee will have information regarding when and where the 
interview will take place.  If the interview runs over a specified time the peer will attempt to contact 
the interviewer (direction taken from Lancaster University Guidance on Safety in Fieldwork (Lone 
Worker) http://www.lancs.ac.uk/depts/safety/files/Fieldwork.pdf.). 
Anonymity 
Participants may be concerned that information will be identifiable.  All identifiable 
information will be anonymised with the agreement of the participant.  Participants’ names will be 
anonymised using pseudonyms. This will also be discussed prior to the interview starting and 
participants will be informed that the field supervisor, clinical psychologist at the hospital, will not 
hear the interview or see the transcript and will only have access to the emerging themes.  It will also 
be highlighted to participants that their care will not be affected by taking part in the study and that 
their participation is voluntary.  Participants will be informed that the results of the study will be fed 
back to the participants if they request it and to the transplant units.  The study will also be written up 
for publication.   
Informed consent will be managed by the provision of clear information, on the participant 
information sheet and through discussion of the process with the chief investigator both prior to 
registering interest and prior to signing a consent form.  Participants will be informed that their 
confidentiality will be maintained, unless risk to either self or other is indicated.  The chief 
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investigator will be aware of the appropriate staff to contact and inform, and the relevant complaints 
procedure.   
Distress 
It is not anticipated that the nature of the questions will be experienced as intrusive or 
distressing.  Participants will be aware that the interview will involve talking about their experiences 
of VAD before they provide consent to take part in the study.   However, these interviews may still 
result in some distress as participants will be talking about difficult experiences.  If a participant was 
to become distressed during the interview, the interview would be stopped and the participant given 
some time.  All participants will be made aware that they are able two withdraw their data at any time 
during the interview and up to two weeks after this date.   
Procedure if a participant becomes distressed 
• Should the participant become distressed during the interview they would be informed that 
they can meet with a clinical psychologist from the unit, for support.  Should the participant 
wish to meet with a clinical psychologist this would be arranged by the chief investigator.  A 
phone call with a clinical psychologist will be provided 24 hours following the request during 
the working week and meeting with a clinical psychologist could be provided within one 
week of the request for support. 
• Should the participant become distressed following the interview the debrief sheet (Appendix 
G) includes the contact details for a clinical psychologist, to allow them to arrange a session 
themselves.   
• As an additional precaution, participants will not be interviewed on a Friday afternoon to 
ensure that staff at the unit would be available to provide support if needed immediately 
following the interview.  
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Appendix  A  
 
Study Title: The experiences of people following short term VAD implant as an emergency 
procedure 
Version number: 1 
Date: June 2016 
Semi-structured interview schedule 
The following schedule will be used as a guide for the researcher, in order to facilitate 
participants to discuss their experiences. However the questions may be adapted or 
changed depending on individuals’ responses. 
• Background to research; purpose of interview; any questions 
 
• Introduction: Thank you for meeting with me today.  My name is Ellie.  You might 
remember from the information sheet that I have a few questions I would like to ask 
you.  It should take about an hour.  You do not have to answer any questions if you 
do not want to.  If you want to stop at any time, let me know and we will stop.  What 
we talk about will be kept annonymised.  However, if you tell me that you or 
someone else is being harmed then I will have to report this to a relevant member of 
staff to keep you or someone else safe.  
 
• I have a digital recorder here to record our interview.   This will make sure I have got 
what you said right.  
 
• Before we start we’ll go through the information sheet, to see if you have any 
questions.  After that I will ask you to sign a consent form, which asks whether you 
understand what is involved in taking part and whether you agree to take part in the 
project.   
 
Establishing rapport and general information  
To help me to understand your experiences I wonder if it would be ok for me to ask you a 
few short questions about your ST VAD 
• The factors that led to ST-VAD 
• What was the diagnosis that led to the emergency procedure 
• How old were you when you the emergency procedure occurred 
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• How long did you have to wait to be taken of ST-VAD and what was the next 
treatment/intervention 
• How long were you in hospital 
• How long has it been since you came off ST-VAD 
Experiences: 
Would it be ok for me to ask you about your experience in order starting with life before the 
emergency procedure? 
• What was life like before you needed the STVAD 
o Relationships, interests, work, health 
• Had you had any experience of ST VAD or heart conditions? Did you know anyone 
who had STVAD 
During 
• What was it like when you needed the STVAD 
o Any changes noticed 
• How did you feel/what did you think about 
• What were your expectations 
• What actually happened  
• What support did you need during this time 
After 
Transition to further intervention 
• Aftermath/experience of being on STVAD 
• Personal impact – has ST VAD/emergency procedure made a difference to how you 
see yourself?  
• How would you say you have changed?  
• What about the way other people see you?   
• Impact of hospital admission, discharge, later interventions. 
• Impact on others: Impact of hospital admission, discharge, later interventions. 
• What support do you need now 
Future 
• What are your expectations about the future? 
• What are your hopes for the future? 
• What support do you think you might need in the future? 
Is there anything that you feel you have not had chance to say about your experience? 
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Do you have any questions? 
 
Additional questions 
1. In the information sheet, that we went through before we started the interview, it 
mentioned that you would be given the opportunity to choose an alternative name for 
yourself that I can use in writing up this project.  Do you want to choose an alternative 
name? 
2. The information sheet also mentioned that I would ask whether you would like to comment 
on a summary of your interview? Your comments may be used in the write up. 
3. I also want to ask you whether you would like to receive a summary of the research that I 
am doing.  This would be posted to you and would be in May or June 2017. 
Remind participants about reimbursement of travel expenses. 




















Participant Information Sheet 
 
The experiences of people following short term VAD implant as an emergency procedure. 
 
Why are we interested in talking to you? 
 
You are someone who has had a Short Term VAD as an emergency procedure.  Talking to 
you about your experiences will help us learn what it is like to have this procedure and life 
afterwards.  It is hoped that this will help services to support similar people better in the 
future.   
 
Do I have to take part? 
 
No.  It’s completely up to you to decide whether or not you take part.  If you decide to take 
part you can change your mind at anytime.  You will not have to give a reason for changing 
your mind.  Taking part or not taking part will not change the care you would receive from 
the hospital.  I am not part of the hospital.  I am a trainee clinical psychologist at Lancaster 
University and I am doing this project as part of my training.   
 
What would I have to do? 
 
If you decide to take part, I will meet with you either in a room at the Transplant Unit or at 
your home if you prefer.  Your travel expenses, including parking, can be refunded up to 
£20.  If you are travelling by car all that will be needed is the number of miles you will travel 
for the interview.  If you are parking you will need to provide a receipt from the car park.  If 
you are using public transport you will need to bring your receipts.  If it is not possible for us 
to meet at your home or at the Transplant Unit, then interviews could be conducted via 
telephone or Skype.    
 
The interview will involve talking about your experience of being on Short Term VAD.  This 
will last about 1 hour.  You could choose to split this time over two sessions if you prefer.  
The interview will be audio recorded.  This is so I can record everything you said correctly.  
The recordings will be deleted when they have been typed up.  
 
At the end of the interview I will ask you three things.  First, whether you would like to 
choose an alternative name that can be used to refer to your words and phrases.  Second, 
whether you would like the opportunity to comment on a summary of your interview.  
These comments may be included in the write up of the research.  Thirdly, whether you 
would like a summary of the results after the research is completed; this could be provided 
by telephone or by post.   
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Will my data be confidential? 
 
The information you provide will be annonymised.  Personal data will be confidential. The 
data collected for this study will be stored securely and only the researchers conducting this 
study will have access to this data: 
o Audio recordings will be deleted after the project has been submitted and marked. 
o Your audio recording or typed up interview may be listened to or read by my 
supervisor at the university. 
o The data files will be encrypted (that is, no-one other than the researcher will be 
able to access them) and the computer itself password protected.  
o The typed version of your interview will be made anonymous by removing any 
identifying information including your name. Anonymised direct quotations from 
your interview may be used in the reports or publications from the study 
o A written transcript of the interview will be kept for 10 years after the study has 
finished. 
There are some limits to confidentiality: if what is said in the interview makes me think that 
you, or someone else, are at significant risk of harm, I will have to break confidentiality and 
speak to someone involved with your care.  If possible, I will tell you if I have to do this. 
 
What will happen to the results? 
The results will be summarised in a report and may be submitted for publication in an 
academic or professional journal. 
 
What will happen if I get upset? 
 
I will not be asking any questions which are intended to upset you.  But sometimes talking 
about our experiences can be upsetting.  If you become upset in the interview we would 
stop.  I would ask you whether you thought you needed any additional support and we 
could talk about what this might be.  I would remind you of your right to decide not to take 
part in the research, this would be your decision and would not affect the support that 
would be offered to you.  You can also change your mind up to two weeks after meeting 
with me, and decide that you do not want your interview to be part of the research.  You 
will be given contact details of people in the hospital that would be able to provide you with 
support after the interview.   
 
Are there any benefits to taking part? 
Although you may find participating interesting, there are no direct benefits of taking part.  
It is hoped that the information gathered by the research may help to shape the service for 
people who are supported with a short term VAD. 
 
What do I do now? 
There are two ways you can get more information about the research or register your 
interest to take part: 
1. You can complete the enclosed expression of interest form and give it to a member 
of staff during outpatient appointment.  They might ask you about this when they 
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first tell you about the research.  If you prefer, you can also post this form to me in 
the stamped addressed envelope enclosed.  
2. You can telephone, text or email me, and I will get back to you 
Telephone: 07508 375658 
Email: e.taylor@lancaster.ac.uk 
 
I will interview up to 12 people for this research.  Participants will be selected on a first 
come first served basis.  
 
Thank you for reading this. 





This study has been reviewed by the Faculty of Health and Medicine Research Ethics 
Committee and approved by the Local NHS Ethics committee. 
 
Complaints  
If you wish to make a complaint or raise concerns about any aspect of this study and do not 
want to speak to the researcher, you can contact:  
 
Bill Sellwood 
Research Director  
Tel: (01524) 593998 
Email: b.sellwood@lancaster.ac.uk 
Clinical Psychology, Div. Of Health Research, 











Staff information Sheet 
The experiences of people following short term VAD implant as an emergency procedure 
This information sheet is for staff who are sharing information about this research project 
with service users they are working with.  If you have any questions please contact me at 
the phone/email below or speak to Zoey Malpus (0161 291 2200).  
Who can take part in the research? 
Anyone who has had an external short term VAD.  They need to have been discharged.  
Potential participants also need to be able to speak English.  Potential participants need to 
be able to consent to taking part in the research. 
When should information about the research project be shared with service users? 
When you have identified people who could take part, information about the research 
project could be shared with services users in their next outpatient appointment.  If this is 
not possible then the same information packs could be posted to the service user identified 
or information given verbally over the phone.  If people express an interest over the phone 
and want more information then packs can be posted to them.   
How to introduce the research project? 
You might introduce the project by saying:  
I have been asked to tell you about some research that is going to be happening.  
Ellie Taylor, from Lancaster University, is interested in talking to you about what it was like 
to be on a short term ventricular assist device and what happened after being on the device.  
The idea is that the experiences people share with Ellie can be used to improve services and 
support for people who have had short term VAD.   
If this is something that you think you’d like to be involved in, Ellie has given me 
some further information that I can give to you.  In this pack it tells you a bit more about the 
project and how to contact Ellie if you have any questions or want to take part. 
If you would like Ellie to contact you with more information or about taking part in 
the research there is a form (expression of interest form) you can fill in.   
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Details for contacting Ellie 
Ellie Taylor 
Telephone: 07508 375658 
Email: e.taylor@lancaster.ac.uk 
Thank you very much for your time and your assistance in helping with recruitment for this 
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Study Title: The experiences of people following short term VAD implant as an emergency 
procedure 
 
We are asking if you would like to take part in a research project which aims to explore the 
experiences of people following short term VAD implant as an emergency procedure. 
Before you consent to participating in the study we ask that you read the participant information 
sheet and mark each box below with your initials if you agree.  If you have any questions or queries 
before signing the consent form please speak to the Chief investigator, Ellie Taylor.  
1. I confirm that I have read the participant information sheet (version 3) and fully 
understand what is expected of me within this study 
 
 








4. I understand that my interview will be audio recorded and then made into an 
anonymised written transcript. 
 
 
5. I understand that digital audio recordings will be kept until the research project 
has been examined.  
 
 
6. The interview will be typed out. I know that the typed out copies of my 
interview will only be read by Ellie and her supervisor.   
 
 
7. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my legal rights being affected. 
 
 
8. I understand that once my data have been anonymised and incorporated into 
themes it might not be possible for it to be withdrawn, though every attempt 
will be made to extract my data, up to the point of publication.  
 
 
9. I understand that the information from my interview will be pooled with other 
participants’ responses, anonymised and may be published. 
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10. I understand that data collected from the study may be seen by regulatory 
authorities or by persons from the Trust where it is relevant to my taking part in 
this study.  I agree to these persons having access to this information.  
 
11. I know that Ellie will use some of my words and phrases in her write up of the 
project.  These will also be used in presentations and if the study is published.  I 
consent to anonymised information and quotations from my interview being 
used in reports, conferences and training events.  
 
 
12. I understand that any information I give will remain strictly confidential and 
anonymous unless it is thought that there is a risk of harm to myself or others, 




13. I consent to Lancaster University keeping a written transcript of the interview 
for 10 years after the study has finished.  
 
 
14. I will be given the opportunity to comment on a summary of my interview.  I 
know that Ellie may use some of my comments in her writing up. 
 
 
15. I know that taking part is my choice and I can change my mind at any time, 
including up to 2 weeks after the meeting. 
 
 





Name of Participant________________Signature_______________Date___________ 
Name of Chief Investigator________________Signature_______________Date___________ 
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Appendix E  
 
  






The experiences of people following short term VAD implant as an emergency procedure  
 
Expression of Interest Form 
I have been told about this research and have been given the information sheet. 
I would: 
(please tick) 
 have some questions I would like to ask about the research to 
help me to decide whether I would like to take part 
 
























The experiences of people following short term VAD implant as an 
emergency procedure 
Debrief sheet 
Thank you for taking part in this research 
What happens next? 
As we discussed, Ellie will contact you with a summary of your interview.  Ellie will ask you 
to provide your comments on this summary.  
Following this, a summary which captures all of the interviews will be produced.  Ellie will 
post or email a copy of this to you. 
What happens with my travel expenses? 
If you travelled by car all that is needed to claim your travel expenses back is your mileage, 
which Ellie will ask you about either before or during the interview. 
If you travelled by public transport you will need to provide receipts of your travel.  You may 
need your receipt for your return journey.  You will be given a travel expenses form to 
complete and a freepost envelope to return the expenses form with your receipts.   
What happens if I feel I need support after the interview? 
If you would like to talk to a member of the Transplant Team then please ask to speak to Dr 
Zoey Malpus, Consultant Clinical Psychologist for transplant. You can speak to her by 
telephoning the transplant Unit on 0161 291 2200.  
 
Thank you again for your invaluable contribution to this research.  Please do not hesitate to 
contact me if you require further information 
Ellie Taylor 
Telephone:  07508 375658  Email: e.taylor@lancaster.ac.uk 
 
  





The experiences of people following short term Ventricular Assist Device (VAD) implant as 
an emergency procedure  
 
Dear Sir or Madam 
Re: The experiences of people following short term VAD implant as an emergency 
procedure 
My name is Ellie Taylor.  I am a Trainee Clinical Psychologist at Lancaster University.  
As part of my training I am going to do some research on what it is like to have a 
short term VAD as an emergency procedure.   
You were recently informed about the research by someone at the hospital.  I am 
interested in talking to you about your experience of having a short term VAD and 
hearing about what this was like for you.  
If you think you would like to talk to me about these things, please read the 
information sheet enclosed.  It provides you with more information about what 
would be involved in taking part in this research.  It also tells you how to contact me 
if you want to ask questions or choose to take part.  
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Appendix K HRA provisional opinion letter 
 
 
North West - Lancaster Research Ethics Committee 
Barlow House 
3rd Floor  
4 Minshull Street  
Manchester 
M1 3DZ 




14 September 2016  
 
Ms Eleanor Taylor 
Trainee Clinical Psychologist  
Lancashire Care NHS Foundation Trust  
Division of Health Research 
Furness Building  




Dear Ms Taylor 
 
 
Study Title: What are the experiences of people following short term VAD 
implant as an emergency procedure 
REC reference: 16/NW/0631 
IRAS project ID: 205179 
 
The Research Ethics Committee reviewed the above application at the meeting held on 08 




The Committee is unable to give an ethical opinion on the basis of the information and 
documentation received so far. Before confirming its opinion, the Committee requests that 
you provide the further information set out below. 
 
Authority to consider your response and to confirm the Committee’s final opinion has been 
delegated to the Chair. 
 
Further information or clarification required 
 
a. The Committee would like to see a follow up letter for recruitment to replace the 
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telephone call 
b. The Committee would like to see the Participant Information Sheet revised to 
i) State that only 12 participants are needed and that if more 
volunteer they will be selected on a first come first served basis 
ii) State whether parking expenses will be paid 
c. The Committee would like to see the Poster revised to 
i) State Ventricular Assist Device rather than VAD 
d. The Committee would like to see the Consent Form revised to 
i) include the version number of the Participant Information Sheet 
which has been read at point 1 
ii) Include the regulatory clause “I understand that data collected from 
the study may be seen by regulatory authorities or by persons from 
the Trust where it is relevant to my taking part in this study. I agree 
to these persons having access to this information” 
iii) line up the boxes with the statements 
iv) omit points 13 and 14 
 
 
If you would find it helpful to discuss any of the matters raised above or seek further 
clarification from a member of the Committee, you are welcome to contact Carol 
Ebenezer whose contact details are on this letter. 
 
When submitting a response to the Committee, the requested information should be 
electronically submitted from IRAS.  A step-by-step guide on submitting your response to the 




Please submit revised documentation where appropriate underlining or otherwise highlighting 
the changes which have been made and giving revised version numbers and dates. You do 
not have to make any changes to the REC application form unless you have been 
specifically requested to do so by the REC. 
 
The Committee will confirm the final ethical opinion within a maximum of 60 days from the 
date of initial receipt of the application, excluding the time taken by you to respond fully to the 
above points.  A response should be submitted by no later than 14 October 2016. 
 
Summary of the discussion at the meeting 
The Chair welcomed you to the REC and thanked you for attending to discuss the study. 
 
Social or scientific value; scientific design and conduct of the study 
The Committee asked whether there had been any service user involvement in the design of 
the study. 
 
You said that the information pack had been seen by a group of buddies at the transplant 
unit. 
 
The Committee asked for a definition of short term VAD. 
 
You said that this would usually be used in the ICU whereas the long term version can be 
used by patients being discharged. 
 
 
ETHICS   4-78 
 
The Committee asked whether the patients would know that they had had short term VAD. 
You confirmed that they would. 
 
Recruitment arrangements and access to health information, and fair participant 
selection 
The Committee noted that 12 participants would be required and as how regularly the 
intervention was performed. 
 
You said that it was quite specialised and that you saw 10 – 15 patients per year so there 
would be 45 potential candidates. 
 
The Committee asked what would happen if more than 12 volunteered. 
 
You said you would use a first come first served basis. 
 
The Committee noted the intention to follow up with a telephone call and commented that this 
could be considered coercive. The Committee requested a letter instead of a telephone call. 
 
You agreed to this. 
 
Care and protection of research participants; respect for potential and enrolled 
 participants’ w elfare and dignity  
The Committee asked who would transcribe the interviews. 
 
You said you would do this yourself. 
 
The Committee queried the arrangements for getting support if a participant became 
distressed and asked whether they could see someone earlier than within a week. 
 
You said that you had thought about this and had considered including a number for the 
Samaritans. However, the buddies rejected this idea. 
 
The Committee asked whether any other support was available, e.g. any other psychologists 
in the area. 
 
You said you would ask about this.  You told the Committee you thought they would be seen 
as soon as possible depending on the severity of the problem. 
 
The Committee asked whether it was possible that some patients would still be in the hospital 
where more support would be on hand. 
 
You said that it was possible that some participants would have been discharged from the 
ICU but still a patient on another ward. 
 
The Committee asked how often the patients came back as outpatients. 
 
You said that as some would have been seen three years previously, you would be able to 
see them in the outpatients department. 
 
The Committee asked how participants would be able to distinguish between the long term 
and short term VAD memories. 
 
You said that it might be difficult but that the short term one would have been when they were 
in patients. 
ETHICS   4-79 
 
 
The Committee suggested it might be better to focus on recovered patients and it was agreed 
that wherever possible the interviews would be carried out in the hospital and that you would 
look for additional psychologists who would be able to see any distressed participants 
quicker. 
 
The Committee asked whether car parking expenses would be paid. 
 
You said you did not know. 
 
Informed consent process and the adequacy and completeness of participant 
information The Committee advised that they would require changes to the Participant 
Information Sheet and Consent Form (as above) and that these would be in the decision 
letter. 
 
Suitability of supporting information 
The Committee told you that the Poster did not stand out and suggested you might like to 
make some changes, e.g. adding colour, to attract attention. Should such changes be made 
they should come to the Committee as part of the response to the REC’s decision. The 
Committee asked that Ventricular Assist Device be stated in full rather than using the 
abbreviation. 
 
You asked the Committee whether you should put additional telephone numbers in the 
Information Sheet. The Committee told you to go along with the buddies’ recommendations 
and leave this out. 
 




The documents reviewed at the meeting were: 
 
Document Version Date 
Copies of advertisement materials for research participants 
[Poster] 
1 01 June 2016 
Evidence of Sponsor insurance or indemnity (non NHS 
Sponsors only) [Insurance Document] 
  
Interview schedules or topic guides for participants [interview 
schedule] 
1 01 June 2016 
IRAS Application Form [IRAS_Form_04082016]  04 August 2016 
IRAS Application Form XML file [IRAS_Form_04082016]  04 August 2016 
Letter from sponsor [IRAS sponsorship letter]   
Other [Staff information sheet] 1 01 June 2016 
Other [Participant expression of interest form] 1 01 June 2016 
Other [Participant debrief sheet] 1 01 June 2016 
Other [Insurance Document professional negligence]   
Participant consent form [Consent form] 1 01 June 2016 
Participant information sheet (PIS) [PIS] 1 01 June 2016 
Research protocol or project proposal [STVAD protocol] 1 01 June 2016 
Summary CV for Chief Investigator (CI) [Chief investigator CV] 1 01 June 2016 
Summary CV for supervisor (student research) [supervisor CV]   
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Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed on the attached 
sheet 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 




Dr Lisa Booth Chair 
 
Email: nrescommittee.northwest-lancaster@nhs.net 
Enclosures: List of names and professions of members who were present at the meeting 
and those who submitted written comments. 
Copy to:           Dr Diane Hopkins 
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North West - Lancaster Research Ethics Committee Attendance at Committee meeting 




Name Profession Present Notes 
Dr Brenda Ashcroft Retired Lecturer Yes  
Mr David Barber Pharmacist Yes  
Dr Lisa Booth Senior Lecturer / Chair Yes  
Ms Debbie Foord Retired community 
psychiatric nurse 
Yes  
Dr Grace Hurford Senior Lecturer, public 
services leadership 
Yes  
Dr Brenda Leese Retired Health 
Researcher 
Yes  
Dr Laura Machin Lecturer in Medical 
Ethics 
Yes  
Dr Anas Olabi Consultant 
Paediatrician 
No  
Mrs Susan Page Senior Clinical Tutor Yes  
Mrs Gillian Rimington Paralegal No  
Mrs Valerie Skinner Nurse (Retired) No  
Professor Jois Stansfield Professor of Speech 
Pathology 
Yes  
Dr Gary Whittle Consultant in Dental 
Public Health (retired) 
Yes  
 
Also in attendance: 
 
Name Position (or reason for attending) 
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Appendix L HRA favourable opinion letter 
 
North West - Lancaster Research Ethics Committee 
 
Barlow House 
3rd Floor  
4 Minshull Street  
Manchester 
M1 3DZ 













30 September 2016 
 
Ms Eleanor Taylor 
Trainee Clinical Psychologist  
Lancashire Care NHS Foundation Trust  
Division of Health Research 





Dear Ms Taylor 
 
Study title: What are the experiences of people following short term VAD 
implant as an emergency procedure 
REC reference: 16/NW/0631 
IRAS project ID: 205179 
 
Thank you for responding to the Committee’s request for further information on the above 
research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this opinion letter.  Should you wish to provide a substitute contact point, require  
Please note:  This is the 
favourable opinion of the REC 
only and does not allow you to 
start your study at NHS sites in 
England until you receive HRA 
Approval 
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further information, or wish to make a request to postpone publication, please contact the 
REC Manager, Mrs Carol Ebenezer, nrescommittee.northwest-lancaster@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
 
Management permission must be obtained from each host organisation prior to the start of 
the study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk. 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees). 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part 
of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS. 
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It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 




The final list of documents reviewed and approved by the Committee is as follows: 
Document Version Date 
Copies of advertisement materials for research participants 
[Poster] 
2 27 September 
2016 Evidence of Sponsor insurance or indemnity (non NHS 
Sponsors only) [Insurance Document] 
  
Interview schedules or topic guides for participants [interview 
schedule] 
1 01 June 2016 
IRAS Application Form [IRAS_Form_04082016]  04 August 2016 
IRAS Application Form XML file [IRAS_Form_04082016]  04 August 2016 
Letter from sponsor [IRAS sponsorship letter]   
Other [Staff information sheet] 1 01 June 2016 
Other [Participant expression of interest form] 1 01 June 2016 
Other [Participant debrief sheet] 1 01 June 2016 
Other [Insurance Document professional negligence]   
Other [Participant Follow up letter] 1 27 September 
2016 Other [HRA schedule of activities ] 1 27 September 
2016 Other [HRA statement of activities] 1 27 September 
2016 Participant consent form [Consent form] 2 27 September 
2016 Participant information sheet (PIS) [PIS] 2 27 September 
2016 Research protocol or project proposal [STVAD protocol] 1 01 June 2016 
Summary CV for Chief Investigator (CI) [Chief investigator CV] 1 01 June 2016 
Summary CV for supervisor (student research) [supervisor CV]   
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
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• Adding new sites and investigators 
 
• Notification of serious breaches of the protocol 
 
• Progress and safety reports 
 
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 





The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the 
feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-








16/NW/0631 Please quote this number on all correspondence 
 












Enclosures: “After ethical review – guidance for researchers” 
 
Copy to: Dr Diane Hopkins 
Lindsay Murray, University Hospital of South Manchester NHS 
Foundation Trust 
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Appendix M IRAS sponsorship letter 
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Appendix N Insurance Document 1 
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Appendix O Insurance Document 2 
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